https://trial.medpath.com/news/first-in-class-stat3-inhibitor-shows-promise-in-feline-head-and-neck-cancer-trial-with-human-applications 2025-08-28T22:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-class-stat3-inhibitor-shows-promise-in-feline-head-and-neck-cancer-trial-with-human-applications 2025-08-28T22:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/novel-frizzled-7-antibody-shows-promise-against-wilms-tumor-through-wnt-pathway-disruption 2025-08-28T22:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-frizzled-7-antibody-shows-promise-against-wilms-tumor-through-wnt-pathway-disruption 2025-08-28T22:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/abeona-therapeutics-expands-manufacturing-capacity-following-fda-approval-of-first-gene-therapy-for-rare-skin-disorder 2025-08-28T22:10:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abeona-therapeutics-expands-manufacturing-capacity-following-fda-approval-of-first-gene-therapy-for-rare-skin-disorder 2025-08-28T22:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/nih-awards-8-4-million-to-ohsu-scientists-to-develop-hiv-cure-through-study-of-three-cured-patients 2025-08-28T22:10:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-awards-8-4-million-to-ohsu-scientists-to-develop-hiv-cure-through-study-of-three-cured-patients 2025-08-28T22:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/lyme-disease-pipeline-shows-promise-with-7-therapies-in-development-as-valneva-pfizer-vaccine-advances 2025-08-28T22:10:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lyme-disease-pipeline-shows-promise-with-7-therapies-in-development-as-valneva-pfizer-vaccine-advances 2025-08-28T22:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/raina-biosciences-publishes-breakthrough-ai-platform-for-mrna-therapeutics-in-science 2025-08-28T22:09:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/raina-biosciences-publishes-breakthrough-ai-platform-for-mrna-therapeutics-in-science 2025-08-28T22:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/photopharmics-forms-commercial-advisory-board-to-guide-fda-breakthrough-device-launch-for-parkinson-s-disease 2025-08-28T22:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/photopharmics-forms-commercial-advisory-board-to-guide-fda-breakthrough-device-launch-for-parkinson-s-disease 2025-08-28T22:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-closes-pennsylvania-facility-cuts-130-jobs-in-strategic-consolidation 2025-08-28T18:11:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exelixis-closes-pennsylvania-facility-cuts-130-jobs-in-strategic-consolidation 2025-08-28T18:11:48+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-partners-with-replicate-bioscience-in-550m-self-replicating-rna-deal-for-obesity-and-diabetes 2025-08-28T18:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-partners-with-replicate-bioscience-in-550m-self-replicating-rna-deal-for-obesity-and-diabetes 2025-08-28T18:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-partners-with-replicate-bioscience-in-550m-deal-for-self-replicating-rna-platform 2025-08-28T18:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-partners-with-replicate-bioscience-in-550m-deal-for-self-replicating-rna-platform 2025-08-28T18:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/cytomed-therapeutics-launches-longevitybank-to-advance-cord-blood-derived-nk-cell-immunotherapies 2025-08-28T18:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomed-therapeutics-launches-longevitybank-to-advance-cord-blood-derived-nk-cell-immunotherapies 2025-08-28T18:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/igc-pharma-receives-patent-allowance-for-thc-microdose-treatment-targeting-tourette-s-syndrome-and-speech-disorders 2025-08-28T18:09:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igc-pharma-receives-patent-allowance-for-thc-microdose-treatment-targeting-tourette-s-syndrome-and-speech-disorders 2025-08-28T18:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/oncotelic-therapeutics-advances-clinical-pipeline-led-by-ceo-s-4-2b-patent-legacy 2025-08-28T18:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncotelic-therapeutics-advances-clinical-pipeline-led-by-ceo-s-4-2b-patent-legacy 2025-08-28T18:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/stramsen-biotech-seeks-fda-approval-to-skip-phase-1-trials-for-plant-based-wound-care-drug-sbx1977 2025-08-28T18:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stramsen-biotech-seeks-fda-approval-to-skip-phase-1-trials-for-plant-based-wound-care-drug-sbx1977 2025-08-28T18:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-als-drug-shows-breakthrough-results-slowing-disease-progression-by-more-than-half 2025-08-28T18:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-als-drug-shows-breakthrough-results-slowing-disease-progression-by-more-than-half 2025-08-28T18:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/clonogenic-hepatocytes-drive-liver-growth-and-enhance-pediatric-gene-therapy-efficacy 2025-08-28T18:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clonogenic-hepatocytes-drive-liver-growth-and-enhance-pediatric-gene-therapy-efficacy 2025-08-28T18:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/bioarctic-reports-strong-q3-2025-results-driven-by-leqembi-royalties-and-novartis-partnership 2025-08-28T18:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioarctic-reports-strong-q3-2025-results-driven-by-leqembi-royalties-and-novartis-partnership 2025-08-28T18:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-and-flagship-pioneering-form-strategic-alliance-to-accelerate-biotech-innovation-through-ai-powered-drug-development 2025-08-28T18:05:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqvia-and-flagship-pioneering-form-strategic-alliance-to-accelerate-biotech-innovation-through-ai-powered-drug-development 2025-08-28T18:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/smartlabs-and-sonrai-analytics-form-strategic-ai-partnership-to-accelerate-precision-medicine-discovery 2025-08-28T18:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smartlabs-and-sonrai-analytics-form-strategic-ai-partnership-to-accelerate-precision-medicine-discovery 2025-08-28T18:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/teva-launches-first-generic-glp-1-weight-loss-drug-as-fda-approves-generic-saxenda 2025-08-28T18:03:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-launches-first-generic-glp-1-weight-loss-drug-as-fda-approves-generic-saxenda 2025-08-28T18:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-class-stat3-inhibitor-shows-promise-in-feline-cancer-trial-with-human-applications 2025-08-28T18:03:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-class-stat3-inhibitor-shows-promise-in-feline-cancer-trial-with-human-applications 2025-08-28T18:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-health-performs-world-s-first-procedure-with-abbott-s-advanced-mitraclip-and-triclip-g5-valve-repair-system 2025-08-28T18:02:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-health-performs-world-s-first-procedure-with-abbott-s-advanced-mitraclip-and-triclip-g5-valve-repair-system 2025-08-28T18:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-tuberculosis-drug-targets-and-novel-therapeutic-strategies-show-promise-against-drug-resistant-strains 2025-08-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-tuberculosis-drug-targets-and-novel-therapeutic-strategies-show-promise-against-drug-resistant-strains 2025-08-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immuneoncia-partners-with-wuxi-biologics-to-advance-anti-pd-l1-cd47-bispecific-antibody-ioh-001 2025-08-28T14:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneoncia-partners-with-wuxi-biologics-to-advance-anti-pd-l1-cd47-bispecific-antibody-ioh-001 2025-08-28T14:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-halts-uk-mounjaro-shipments-ahead-of-170-price-increase 2025-08-28T14:05:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-halts-uk-mounjaro-shipments-ahead-of-170-price-increase 2025-08-28T14:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-approves-four-new-drugs-under-accelerated-1-mechanism-including-iga-nephropathy-treatment 2025-08-28T14:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-approves-four-new-drugs-under-accelerated-1-mechanism-including-iga-nephropathy-treatment 2025-08-28T14:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/nih-awards-2-8-million-grant-to-develop-next-generation-brain-implant-for-drug-resistant-epilepsy 2025-08-28T14:05:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-awards-2-8-million-grant-to-develop-next-generation-brain-implant-for-drug-resistant-epilepsy 2025-08-28T14:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/ensilitech-raises-ps4-5m-to-eliminate-cold-chain-dependency-with-room-temperature-stable-biopharmaceuticals 2025-08-28T14:04:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensilitech-raises-ps4-5m-to-eliminate-cold-chain-dependency-with-room-temperature-stable-biopharmaceuticals 2025-08-28T14:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-expands-biosimilar-portfolio-in-vietnam-s-7-3-billion-biopharmaceutical-market 2025-08-28T14:03:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-expands-biosimilar-portfolio-in-vietnam-s-7-3-billion-biopharmaceutical-market 2025-08-28T14:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-receives-fda-orphan-drug-designation-for-novel-jak2-selective-antisense-therapy-vgt-1849b-in-polycythemia-vera 2025-08-28T14:03:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-pharmaceuticals-receives-fda-orphan-drug-designation-for-novel-jak2-selective-antisense-therapy-vgt-1849b-in-polycythemia-vera 2025-08-28T14:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/texas-house-passes-bill-allowing-over-the-counter-ivermectin-sales-without-prescription 2025-08-28T10:13:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-house-passes-bill-allowing-over-the-counter-ivermectin-sales-without-prescription 2025-08-28T10:13:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-covid-19-vaccines-for-high-risk-populations-with-mandatory-post-marketing-studies 2025-08-28T10:09:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-covid-19-vaccines-for-high-risk-populations-with-mandatory-post-marketing-studies 2025-08-28T10:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/gc-biopharma-advances-two-dose-varicella-vaccine-barycela-to-phase-3-trial-in-thailand 2025-08-28T10:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gc-biopharma-advances-two-dose-varicella-vaccine-barycela-to-phase-3-trial-in-thailand 2025-08-28T10:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-based-medical-products-show-sustained-sleep-quality-improvements-in-18-month-insomnia-study 2025-08-28T10:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cannabis-based-medical-products-show-sustained-sleep-quality-improvements-in-18-month-insomnia-study 2025-08-28T10:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/circio-s-circvec-technology-achieves-40x-enhancement-in-aav-gene-therapy-vectors 2025-08-28T10:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circio-s-circvec-technology-achieves-40x-enhancement-in-aav-gene-therapy-vectors 2025-08-28T10:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-federal-court-of-appeal-rules-on-patent-register-timing-in-bayer-vs-amgen-case 2025-08-28T10:05:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canadian-federal-court-of-appeal-rules-on-patent-register-timing-in-bayer-vs-amgen-case 2025-08-28T10:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/network-meta-analysis-reveals-optimal-chinese-herbal-preparations-for-gastric-cancer-treatment 2025-08-28T10:05:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/network-meta-analysis-reveals-optimal-chinese-herbal-preparations-for-gastric-cancer-treatment 2025-08-28T10:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-orphan-drug-incentives-and-patient-advocacy-drive-rare-disease-drug-development 2025-08-28T10:04:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-orphan-drug-incentives-and-patient-advocacy-drive-rare-disease-drug-development 2025-08-28T10:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/biophytis-receives-ema-and-belgian-regulatory-approval-for-phase-3-sarcopenia-trial 2025-08-28T10:04:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biophytis-receives-ema-and-belgian-regulatory-approval-for-phase-3-sarcopenia-trial 2025-08-28T10:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/mrd-testing-emerges-as-key-tool-for-value-based-care-in-multiple-myeloma-treatment 2025-08-28T10:04:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrd-testing-emerges-as-key-tool-for-value-based-care-in-multiple-myeloma-treatment 2025-08-28T10:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/knowledge-gaps-persist-in-understanding-adc-efficacy-for-nsclc-brain-metastases 2025-08-28T10:03:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/knowledge-gaps-persist-in-understanding-adc-efficacy-for-nsclc-brain-metastases 2025-08-28T10:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/mannkind-and-united-therapeutics-expand-partnership-for-second-pulmonary-hypertension-inhaled-therapy 2025-08-28T06:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mannkind-and-united-therapeutics-expand-partnership-for-second-pulmonary-hypertension-inhaled-therapy 2025-08-28T06:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/acrobiosystems-and-daan-biotherapeutics-form-strategic-alliance-to-accelerate-precision-immuno-oncology-development 2025-08-28T06:02:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acrobiosystems-and-daan-biotherapeutics-form-strategic-alliance-to-accelerate-precision-immuno-oncology-development 2025-08-28T06:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/baylor-genetics-rna-sequencing-studies-show-24-diagnostic-success-rate-for-previously-undiagnosed-rare-diseases 2025-08-28T03:06:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baylor-genetics-rna-sequencing-studies-show-24-diagnostic-success-rate-for-previously-undiagnosed-rare-diseases 2025-08-28T03:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/intensive-gum-disease-treatment-reduces-arterial-thickening-in-randomized-clinical-trial 2025-08-28T02:03:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensive-gum-disease-treatment-reduces-arterial-thickening-in-randomized-clinical-trial 2025-08-28T02:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/tct-2025-unveils-28-late-breaking-cardiovascular-trials-featuring-novel-drug-eluting-technologies-and-ai-enabled-diagnostics 2025-08-28T02:03:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tct-2025-unveils-28-late-breaking-cardiovascular-trials-featuring-novel-drug-eluting-technologies-and-ai-enabled-diagnostics 2025-08-28T02:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-concept-adc-micvotabart-pelidotin-achieves-50-response-rate-in-head-and-neck-cancer-earns-fda-fast-track-designation 2025-08-28T02:02:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-concept-adc-micvotabart-pelidotin-achieves-50-response-rate-in-head-and-neck-cancer-earns-fda-fast-track-designation 2025-08-28T02:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/tas-102-shows-promise-in-clearing-circulating-tumor-dna-in-colorectal-cancer-patients-with-minimal-residual-disease 2025-08-28T02:00:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tas-102-shows-promise-in-clearing-circulating-tumor-dna-in-colorectal-cancer-patients-with-minimal-residual-disease 2025-08-28T02:00:47+00:00 hourly 0.9 https://trial.medpath.com/news/leicester-royal-infirmary-expands-aseptic-pharmacy-to-triple-cancer-treatment-production-capacity 2025-08-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leicester-royal-infirmary-expands-aseptic-pharmacy-to-triple-cancer-treatment-production-capacity 2025-08-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-affirms-patent-priority-for-phmb-based-wound-treatment-in-first-aia-derivation-review 2025-08-27T21:38:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-affirms-patent-priority-for-phmb-based-wound-treatment-in-first-aia-derivation-review 2025-08-27T21:38:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-pemigatinib-for-rare-fgfr1-rearranged-myeloid-lymphoid-neoplasms-following-stanford-led-phase-ii-trial 2025-08-27T21:32:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-pemigatinib-for-rare-fgfr1-rearranged-myeloid-lymphoid-neoplasms-following-stanford-led-phase-ii-trial 2025-08-27T21:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/cartherics-secures-chinese-patent-for-enhanced-nk-cell-therapy-targeting-solid-tumors 2025-08-27T21:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cartherics-secures-chinese-patent-for-enhanced-nk-cell-therapy-targeting-solid-tumors 2025-08-27T21:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/decipher-genomic-test-predicts-chemotherapy-benefit-in-metastatic-prostate-cancer 2025-08-27T21:30:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/decipher-genomic-test-predicts-chemotherapy-benefit-in-metastatic-prostate-cancer 2025-08-27T21:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-gene-signatures-to-predict-cdk4-6-inhibitor-response-in-hormone-positive-breast-cancer 2025-08-27T21:30:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-identify-gene-signatures-to-predict-cdk4-6-inhibitor-response-in-hormone-positive-breast-cancer 2025-08-27T21:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-develop-laser-free-eye-surgery-alternative-using-electrical-current-to-reshape-cornea 2025-08-27T21:30:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-develop-laser-free-eye-surgery-alternative-using-electrical-current-to-reshape-cornea 2025-08-27T21:30:16+00:00 hourly 0.9 https://trial.medpath.com/news/neusoft-medical-systems-receives-nmpa-approval-for-china-s-first-photon-counting-ct-scanner 2025-08-27T21:29:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neusoft-medical-systems-receives-nmpa-approval-for-china-s-first-photon-counting-ct-scanner 2025-08-27T21:29:12+00:00 hourly 0.9 https://trial.medpath.com/news/cuny-researchers-develop-first-broad-spectrum-antiviral-targeting-viral-envelope-glycans 2025-08-27T21:27:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cuny-researchers-develop-first-broad-spectrum-antiviral-targeting-viral-envelope-glycans 2025-08-27T21:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-launches-route-b-pilot-to-streamline-clinical-trial-modifications-ahead-of-2026-regulatory-overhaul 2025-08-27T21:25:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-launches-route-b-pilot-to-streamline-clinical-trial-modifications-ahead-of-2026-regulatory-overhaul 2025-08-27T21:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-verzenio-demonstrates-significant-overall-survival-benefit-in-high-risk-early-breast-cancer 2025-08-27T18:15:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-s-verzenio-demonstrates-significant-overall-survival-benefit-in-high-risk-early-breast-cancer 2025-08-27T18:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/hope-biosciences-receives-first-fda-rmat-designation-for-multiple-sclerosis-stem-cell-therapy 2025-08-27T18:11:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hope-biosciences-receives-first-fda-rmat-designation-for-multiple-sclerosis-stem-cell-therapy 2025-08-27T18:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/prometheus-laboratories-partners-with-celltrion-to-validate-therapeutic-drug-monitoring-for-subcutaneous-infliximab 2025-08-27T18:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prometheus-laboratories-partners-with-celltrion-to-validate-therapeutic-drug-monitoring-for-subcutaneous-infliximab 2025-08-27T18:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-therapeutics-shares-drop-10-following-new-liver-injury-report-for-gene-therapy-elevidys 2025-08-27T18:08:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-therapeutics-shares-drop-10-following-new-liver-injury-report-for-gene-therapy-elevidys 2025-08-27T18:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/allogeneic-cd19-car-t-cell-therapy-shows-promise-for-refractory-lupus-nephritis-in-phase-1-trial 2025-08-27T18:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allogeneic-cd19-car-t-cell-therapy-shows-promise-for-refractory-lupus-nephritis-in-phase-1-trial 2025-08-27T18:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/evommune-initiates-phase-2b-trial-of-oral-mrgprx2-antagonist-evo756-for-moderate-to-severe-atopic-dermatitis 2025-08-27T18:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evommune-initiates-phase-2b-trial-of-oral-mrgprx2-antagonist-evo756-for-moderate-to-severe-atopic-dermatitis 2025-08-27T18:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/azitra-doses-first-patient-in-phase-1-2-trial-of-live-biotherapeutic-for-egfr-inhibitor-associated-rash 2025-08-27T18:05:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azitra-doses-first-patient-in-phase-1-2-trial-of-live-biotherapeutic-for-egfr-inhibitor-associated-rash 2025-08-27T18:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/minovia-therapeutics-secures-350000-grant-to-develop-blood-based-mitochondrial-biomarkers 2025-08-27T18:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minovia-therapeutics-secures-350000-grant-to-develop-blood-based-mitochondrial-biomarkers 2025-08-27T18:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-therapy-exa-cel-delivers-sustained-quality-of-life-improvements-in-blood-disorders 2025-08-27T18:04:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-gene-therapy-exa-cel-delivers-sustained-quality-of-life-improvements-in-blood-disorders 2025-08-27T18:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/wugen-secures-115-million-to-advance-first-in-class-off-the-shelf-car-t-therapy-for-t-cell-malignancies 2025-08-27T18:03:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wugen-secures-115-million-to-advance-first-in-class-off-the-shelf-car-t-therapy-for-t-cell-malignancies 2025-08-27T18:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/amylyx-s-amx0035-fails-mid-stage-trial-for-progressive-supranuclear-palsy 2025-08-27T18:03:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amylyx-s-amx0035-fails-mid-stage-trial-for-progressive-supranuclear-palsy 2025-08-27T18:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/rafael-holdings-reports-78-success-rate-for-npc1-treatment-in-phase-3-pediatric-sub-study 2025-08-27T18:03:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rafael-holdings-reports-78-success-rate-for-npc1-treatment-in-phase-3-pediatric-sub-study 2025-08-27T18:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/moleculin-s-annamycin-shows-promising-survival-data-in-relapsed-aml-phase-1b-2-trial 2025-08-27T18:02:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moleculin-s-annamycin-shows-promising-survival-data-in-relapsed-aml-phase-1b-2-trial 2025-08-27T18:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-confirms-survival-benefits-of-immunotherapy-in-extensive-stage-small-cell-lung-cancer 2025-08-27T18:02:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-evidence-confirms-survival-benefits-of-immunotherapy-in-extensive-stage-small-cell-lung-cancer 2025-08-27T18:02:29+00:00 hourly 0.9 https://trial.medpath.com/news/breath-analysis-technology-achieves-breakthrough-in-predicting-pneumonia-before-symptoms-appear 2025-08-27T18:01:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breath-analysis-technology-achieves-breakthrough-in-predicting-pneumonia-before-symptoms-appear 2025-08-27T18:01:17+00:00 hourly 0.9 https://trial.medpath.com/news/airiver-medical-receives-fda-ide-approval-for-pivotal-trial-of-drug-coated-balloon-in-central-airway-stenosis 2025-08-27T18:00:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/airiver-medical-receives-fda-ide-approval-for-pivotal-trial-of-drug-coated-balloon-in-central-airway-stenosis 2025-08-27T18:00:50+00:00 hourly 0.9 https://trial.medpath.com/news/ms-pharma-opens-first-biologics-manufacturing-facility-in-middle-east-with-50-million-saudi-arabia-investment 2025-08-27T18:00:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ms-pharma-opens-first-biologics-manufacturing-facility-in-middle-east-with-50-million-saudi-arabia-investment 2025-08-27T18:00:45+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-deploys-ai-platform-to-accelerate-clinical-trial-recruitment-across-multiple-specialties 2025-08-27T17:59:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-deploys-ai-platform-to-accelerate-clinical-trial-recruitment-across-multiple-specialties 2025-08-27T17:59:09+00:00 hourly 0.9 https://trial.medpath.com/news/northwest-biotherapeutics-completes-strategic-acquisition-of-advent-bioservices-to-integrate-manufacturing-operations 2025-08-27T16:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwest-biotherapeutics-completes-strategic-acquisition-of-advent-bioservices-to-integrate-manufacturing-operations 2025-08-27T16:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/alivedx-advances-mosaiq-platform-in-us-market-with-fda-device-registration-and-vasculitis-test-submission 2025-08-27T14:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alivedx-advances-mosaiq-platform-in-us-market-with-fda-device-registration-and-vasculitis-test-submission 2025-08-27T14:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/circurna-partners-with-gatc-health-to-accelerate-circular-rna-therapeutics-using-ai-platform 2025-08-27T14:05:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circurna-partners-with-gatc-health-to-accelerate-circular-rna-therapeutics-using-ai-platform 2025-08-27T14:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/treos-bio-launches-pivotal-phase-ii-trial-for-polypepi1018-in-treatment-resistant-colorectal-cancer 2025-08-27T14:02:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treos-bio-launches-pivotal-phase-ii-trial-for-polypepi1018-in-treatment-resistant-colorectal-cancer 2025-08-27T14:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/amylyx-discontinues-amx0035-development-for-progressive-supranuclear-palsy-after-phase-2b-trial-fails-to-meet-primary-endpoints 2025-08-27T14:02:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amylyx-discontinues-amx0035-development-for-progressive-supranuclear-palsy-after-phase-2b-trial-fails-to-meet-primary-endpoints 2025-08-27T14:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/starpharma-advances-dendrimer-drug-delivery-platform-with-genentech-partnership-and-clinical-progress 2025-08-27T14:01:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/starpharma-advances-dendrimer-drug-delivery-platform-with-genentech-partnership-and-clinical-progress 2025-08-27T14:01:27+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-her2-breast-cancer-clinical-trials-report-2025-reveals-global-research-landscape 2025-08-27T14:00:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-her2-breast-cancer-clinical-trials-report-2025-reveals-global-research-landscape 2025-08-27T14:00:29+00:00 hourly 0.9 https://trial.medpath.com/news/cage-bio-initiates-phase-2-trial-of-first-in-class-dna-aptamer-therapy-cgb-600-for-vitiligo-treatment 2025-08-27T12:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cage-bio-initiates-phase-2-trial-of-first-in-class-dna-aptamer-therapy-cgb-600-for-vitiligo-treatment 2025-08-27T12:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-reduce-heart-failure-events-while-cutting-healthcare-carbon-emissions-by-2-billion-kilograms 2025-08-27T10:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-reduce-heart-failure-events-while-cutting-healthcare-carbon-emissions-by-2-billion-kilograms 2025-08-27T10:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-pharma-investment-in-china-surges-to-48-5-billion-in-first-half-of-2025-doubling-2024-total 2025-08-27T10:03:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-pharma-investment-in-china-surges-to-48-5-billion-in-first-half-of-2025-doubling-2024-total 2025-08-27T10:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/osivax-secures-19-5m-barda-award-to-advance-universal-influenza-vaccine-ovx836 2025-08-27T10:02:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osivax-secures-19-5m-barda-award-to-advance-universal-influenza-vaccine-ovx836 2025-08-27T10:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/bioversys-receives-ema-orphan-designation-for-novel-tuberculosis-combination-therapy 2025-08-27T09:57:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioversys-receives-ema-orphan-designation-for-novel-tuberculosis-combination-therapy 2025-08-27T09:57:57+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-funding-surge-153m-for-programmable-mrna-cancer-therapy-leads-major-investment-round 2025-08-27T09:57:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-funding-surge-153m-for-programmable-mrna-cancer-therapy-leads-major-investment-round 2025-08-27T09:57:18+00:00 hourly 0.9 https://trial.medpath.com/news/neuren-pharmaceuticals-reports-record-daybue-royalties-as-rett-syndrome-therapy-sales-exceed-100-million-quarterly-milestone 2025-08-27T09:56:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuren-pharmaceuticals-reports-record-daybue-royalties-as-rett-syndrome-therapy-sales-exceed-100-million-quarterly-milestone 2025-08-27T09:56:59+00:00 hourly 0.9 https://trial.medpath.com/news/altasciences-partners-with-evidence-matters-to-deploy-ai-enhanced-regulatory-writing-technology 2025-08-27T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altasciences-partners-with-evidence-matters-to-deploy-ai-enhanced-regulatory-writing-technology 2025-08-27T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/us-trade-commission-bans-ultrahuman-and-ringconn-smart-rings-following-oura-health-patent-victory 2025-08-27T06:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-trade-commission-bans-ultrahuman-and-ringconn-smart-rings-following-oura-health-patent-victory 2025-08-27T06:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/federal-appeals-court-reinstates-oregon-drug-price-transparency-law-after-phrma-challenge 2025-08-27T06:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-appeals-court-reinstates-oregon-drug-price-transparency-law-after-phrma-challenge 2025-08-27T06:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-vaccines-show-promise-in-clinical-trials-for-glioblastoma-and-other-malignancies 2025-08-27T06:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-vaccines-show-promise-in-clinical-trials-for-glioblastoma-and-other-malignancies 2025-08-27T06:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/virginia-approves-incentive-packages-for-astrazeneca-and-eli-lilly-manufacturing-plants 2025-08-27T05:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virginia-approves-incentive-packages-for-astrazeneca-and-eli-lilly-manufacturing-plants 2025-08-27T05:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/umass-chan-medical-school-partners-with-hongene-biotech-to-expand-access-to-exna-oligonucleotide-technology 2025-08-27T05:55:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/umass-chan-medical-school-partners-with-hongene-biotech-to-expand-access-to-exna-oligonucleotide-technology 2025-08-27T05:55:40+00:00 hourly 0.9 https://trial.medpath.com/news/verily-shuts-down-medical-device-program-as-alphabet-pivots-to-ai-driven-healthcare-strategy 2025-08-27T05:55:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verily-shuts-down-medical-device-program-as-alphabet-pivots-to-ai-driven-healthcare-strategy 2025-08-27T05:55:37+00:00 hourly 0.9 https://trial.medpath.com/news/antiva-biosciences-reports-positive-phase-1b-2-results-for-abi-2280-in-high-risk-hpv-treatment 2025-08-27T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antiva-biosciences-reports-positive-phase-1b-2-results-for-abi-2280-in-high-risk-hpv-treatment 2025-08-27T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/psycho-oncology-emerges-as-essential-component-of-comprehensive-cancer-care 2025-08-27T03:09:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psycho-oncology-emerges-as-essential-component-of-comprehensive-cancer-care 2025-08-27T03:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/er-kim-secures-exclusive-distribution-rights-for-cnx-therapeutics-oncology-portfolio-in-central-eastern-europe-and-turkey 2025-08-27T02:01:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/er-kim-secures-exclusive-distribution-rights-for-cnx-therapeutics-oncology-portfolio-in-central-eastern-europe-and-turkey 2025-08-27T02:01:57+00:00 hourly 0.9 https://trial.medpath.com/news/zentalis-pharmaceuticals-appoints-james-b-bucher-as-chief-legal-officer-to-support-azenosertib-s-advancement 2025-08-27T02:00:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zentalis-pharmaceuticals-appoints-james-b-bucher-as-chief-legal-officer-to-support-azenosertib-s-advancement 2025-08-27T02:00:55+00:00 hourly 0.9 https://trial.medpath.com/news/light-based-therapy-shows-cognitive-improvements-in-alzheimer-s-clinical-trials 2025-08-27T02:00:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/light-based-therapy-shows-cognitive-improvements-in-alzheimer-s-clinical-trials 2025-08-27T02:00:48+00:00 hourly 0.9 https://trial.medpath.com/news/avapritinib-shows-durable-long-term-response-in-indolent-systemic-mastocytosis-as-pipeline-expands 2025-08-27T02:00:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avapritinib-shows-durable-long-term-response-in-indolent-systemic-mastocytosis-as-pipeline-expands 2025-08-27T02:00:28+00:00 hourly 0.9 https://trial.medpath.com/news/eris-lifesciences-receives-anvisa-approval-for-sterile-injectable-facility-enabling-brazil-market-entry 2025-08-27T02:00:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eris-lifesciences-receives-anvisa-approval-for-sterile-injectable-facility-enabling-brazil-market-entry 2025-08-27T02:00:20+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-s-nanyang-biologics-partners-with-tech-giants-to-accelerate-ai-powered-drug-discovery-platform 2025-08-27T02:00:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-s-nanyang-biologics-partners-with-tech-giants-to-accelerate-ai-powered-drug-discovery-platform 2025-08-27T02:00:07+00:00 hourly 0.9 https://trial.medpath.com/news/santersus-receives-second-fda-breakthrough-device-designation-for-nucleocapture-in-systemic-lupus-erythematosus 2025-08-27T01:59:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/santersus-receives-second-fda-breakthrough-device-designation-for-nucleocapture-in-systemic-lupus-erythematosus 2025-08-27T01:59:40+00:00 hourly 0.9 https://trial.medpath.com/news/proxygen-partners-with-epfl-to-advance-ai-driven-molecular-glue-degrader-discovery 2025-08-27T01:58:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proxygen-partners-with-epfl-to-advance-ai-driven-molecular-glue-degrader-discovery 2025-08-27T01:58:19+00:00 hourly 0.9 https://trial.medpath.com/news/mount-sinai-researchers-discover-potent-monoclonal-antibodies-against-mpox-with-complete-protection-in-animal-models 2025-08-26T22:24:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mount-sinai-researchers-discover-potent-monoclonal-antibodies-against-mpox-with-complete-protection-in-animal-models 2025-08-26T22:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/carb-x-awards-1-1-million-to-phiogen-for-novel-bacteriophage-treatment-against-drug-resistant-e-coli-bloodstream-infections 2025-08-26T22:24:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carb-x-awards-1-1-million-to-phiogen-for-novel-bacteriophage-treatment-against-drug-resistant-e-coli-bloodstream-infections 2025-08-26T22:24:04+00:00 hourly 0.9 https://trial.medpath.com/news/briacell-s-cancer-immunotherapy-mechanism-validated-in-nci-collaboration-study 2025-08-26T22:22:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/briacell-s-cancer-immunotherapy-mechanism-validated-in-nci-collaboration-study 2025-08-26T22:22:29+00:00 hourly 0.9 https://trial.medpath.com/news/varian-completes-fast-02-flash-radiotherapy-trial-for-bone-metastases-at-uc-cancer-center 2025-08-26T22:21:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/varian-completes-fast-02-flash-radiotherapy-trial-for-bone-metastases-at-uc-cancer-center 2025-08-26T22:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/advicenne-submits-fda-registration-application-for-sibnayal-r-in-rare-kidney-disease-treatment 2025-08-26T22:20:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advicenne-submits-fda-registration-application-for-sibnayal-r-in-rare-kidney-disease-treatment 2025-08-26T22:20:42+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-s-recell-system-demonstrates-36-reduction-in-hospital-stay-for-burn-patients 2025-08-26T22:19:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avita-medical-s-recell-system-demonstrates-36-reduction-in-hospital-stay-for-burn-patients 2025-08-26T22:19:18+00:00 hourly 0.9 https://trial.medpath.com/news/cornell-researchers-engineer-bacteria-to-produce-therapeutic-antibodies-at-lower-cost 2025-08-26T22:19:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cornell-researchers-engineer-bacteria-to-produce-therapeutic-antibodies-at-lower-cost 2025-08-26T22:19:16+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-secures-expanded-fda-approval-for-repatha-r-in-cardiovascular-risk-management 2025-08-26T22:17:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-secures-expanded-fda-approval-for-repatha-r-in-cardiovascular-risk-management 2025-08-26T22:17:52+00:00 hourly 0.9 https://trial.medpath.com/news/arctx-medical-receives-fda-ide-approval-for-pivotal-trial-of-novel-cooling-therapy-for-acute-pancreatitis 2025-08-26T22:17:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arctx-medical-receives-fda-ide-approval-for-pivotal-trial-of-novel-cooling-therapy-for-acute-pancreatitis 2025-08-26T22:17:05+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-approve-first-in-class-topical-anti-androgen-therapy-for-acne-treatment 2025-08-26T22:16:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-regulators-approve-first-in-class-topical-anti-androgen-therapy-for-acne-treatment 2025-08-26T22:16:55+00:00 hourly 0.9 https://trial.medpath.com/news/novel-immunotherapy-combination-achieves-100-disease-control-in-recurrent-glioblastoma-pilot-study 2025-08-26T22:16:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-immunotherapy-combination-achieves-100-disease-control-in-recurrent-glioblastoma-pilot-study 2025-08-26T22:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-clinical-trials-review-reveals-global-lennox-gastaut-syndrome-research-landscape 2025-08-26T22:16:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-clinical-trials-review-reveals-global-lennox-gastaut-syndrome-research-landscape 2025-08-26T22:16:27+00:00 hourly 0.9 https://trial.medpath.com/news/charles-river-laboratories-joins-eu-backed-easygen-consortium-to-accelerate-bedside-car-t-manufacturing 2025-08-26T18:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charles-river-laboratories-joins-eu-backed-easygen-consortium-to-accelerate-bedside-car-t-manufacturing 2025-08-26T18:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/allarity-therapeutics-receives-fda-fast-track-designation-for-stenoparib-in-advanced-ovarian-cancer 2025-08-26T18:02:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allarity-therapeutics-receives-fda-fast-track-designation-for-stenoparib-in-advanced-ovarian-cancer 2025-08-26T18:02:29+00:00 hourly 0.9 https://trial.medpath.com/news/appia-bio-shuts-down-cell-therapy-operations-after-failed-partnership-with-kite-pharma 2025-08-26T18:02:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/appia-bio-shuts-down-cell-therapy-operations-after-failed-partnership-with-kite-pharma 2025-08-26T18:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/intron-bio-files-patent-applications-for-crispr-cas9-gene-editing-technology-targeting-pasteurella-bacteriophages 2025-08-26T18:01:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intron-bio-files-patent-applications-for-crispr-cas9-gene-editing-technology-targeting-pasteurella-bacteriophages 2025-08-26T18:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/dendritic-cell-vaccine-shows-promise-in-liver-cancer-trial-extending-progression-free-survival 2025-08-26T18:01:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dendritic-cell-vaccine-shows-promise-in-liver-cancer-trial-extending-progression-free-survival 2025-08-26T18:01:15+00:00 hourly 0.9 https://trial.medpath.com/news/polaritybio-completes-phase-iii-enrollment-for-skinte-in-diabetic-foot-ulcers-targeting-first-bla-approval-in-chronic-wounds-since-1997 2025-08-26T18:00:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polaritybio-completes-phase-iii-enrollment-for-skinte-in-diabetic-foot-ulcers-targeting-first-bla-approval-in-chronic-wounds-since-1997 2025-08-26T18:00:24+00:00 hourly 0.9 https://trial.medpath.com/news/curanex-pharmaceuticals-raises-15-million-in-ipo-to-advance-ulcerative-colitis-treatment 2025-08-26T18:00:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curanex-pharmaceuticals-raises-15-million-in-ipo-to-advance-ulcerative-colitis-treatment 2025-08-26T18:00:19+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-first-ever-orphan-drug-designation-for-radiation-maculopathy-treatment 2025-08-26T17:58:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-first-ever-orphan-drug-designation-for-radiation-maculopathy-treatment 2025-08-26T17:58:39+00:00 hourly 0.9 https://trial.medpath.com/news/qlaris-bio-initiates-phase-ii-trial-for-novel-glaucoma-therapy-qls-111-in-south-korea 2025-08-26T17:57:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qlaris-bio-initiates-phase-ii-trial-for-novel-glaucoma-therapy-qls-111-in-south-korea 2025-08-26T17:57:02+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-reports-record-sales-growth-as-ivonescimab-meets-overall-survival-endpoint-in-phase-iii-trial 2025-08-26T17:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akeso-reports-record-sales-growth-as-ivonescimab-meets-overall-survival-endpoint-in-phase-iii-trial 2025-08-26T17:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/mosaic-neuroscience-partners-with-ixcells-to-pioneer-patient-specific-als-disease-models 2025-08-26T17:56:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mosaic-neuroscience-partners-with-ixcells-to-pioneer-patient-specific-als-disease-models 2025-08-26T17:56:55+00:00 hourly 0.9 https://trial.medpath.com/news/sohm-achieves-major-breakthrough-with-abbie-gene-editing-platform-using-advanced-dcas12a-technology 2025-08-26T17:55:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sohm-achieves-major-breakthrough-with-abbie-gene-editing-platform-using-advanced-dcas12a-technology 2025-08-26T17:55:56+00:00 hourly 0.9 https://trial.medpath.com/news/correctsequence-therapeutics-achieves-first-successful-sickle-cell-disease-treatment-in-china-using-base-editing-technology-cs-101 2025-08-26T17:53:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/correctsequence-therapeutics-achieves-first-successful-sickle-cell-disease-treatment-in-china-using-base-editing-technology-cs-101 2025-08-26T17:53:41+00:00 hourly 0.9 https://trial.medpath.com/news/virax-biolabs-partners-with-emory-university-for-long-covid-diagnostic-study-using-t-cell-technology 2025-08-26T17:53:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virax-biolabs-partners-with-emory-university-for-long-covid-diagnostic-study-using-t-cell-technology 2025-08-26T17:53:38+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-iowa-develops-gene-therapy-to-prevent-craniosynostosis-in-newborns 2025-08-26T17:52:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-iowa-develops-gene-therapy-to-prevent-craniosynostosis-in-newborns 2025-08-26T17:52:50+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-launches-first-in-class-linaclotide-for-chronic-constipation-in-india 2025-08-26T17:52:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-launches-first-in-class-linaclotide-for-chronic-constipation-in-india 2025-08-26T17:52:47+00:00 hourly 0.9 https://trial.medpath.com/news/pd-1-pd-l1-inhibitors-show-promise-in-thyroid-cancer-treatment-through-combination-strategies 2025-08-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pd-1-pd-l1-inhibitors-show-promise-in-thyroid-cancer-treatment-through-combination-strategies 2025-08-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zyus-life-sciences-initiates-phase-2a-trial-for-novel-non-opioid-cancer-pain-treatment 2025-08-26T14:05:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zyus-life-sciences-initiates-phase-2a-trial-for-novel-non-opioid-cancer-pain-treatment 2025-08-26T14:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-secures-first-denosumab-biosimilar-approval-in-thailand-expanding-access-to-bone-disease-treatment 2025-08-26T13:56:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-secures-first-denosumab-biosimilar-approval-in-thailand-expanding-access-to-bone-disease-treatment 2025-08-26T13:56:58+00:00 hourly 0.9 https://trial.medpath.com/news/controlled-release-drug-delivery-market-expands-with-major-pharma-investment-in-precision-medicine-technologies 2025-08-26T13:56:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/controlled-release-drug-delivery-market-expands-with-major-pharma-investment-in-precision-medicine-technologies 2025-08-26T13:56:56+00:00 hourly 0.9 https://trial.medpath.com/news/antifibrotic-drug-development-gains-momentum-with-3b-in-deals-and-breakthrough-clinical-results 2025-08-26T13:56:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antifibrotic-drug-development-gains-momentum-with-3b-in-deals-and-breakthrough-clinical-results 2025-08-26T13:56:20+00:00 hourly 0.9 https://trial.medpath.com/news/bioarctic-and-novartis-partner-on-braintransporter-technology-for-neurodegeneration-treatment-development 2025-08-26T13:56:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioarctic-and-novartis-partner-on-braintransporter-technology-for-neurodegeneration-treatment-development 2025-08-26T13:56:17+00:00 hourly 0.9 https://trial.medpath.com/news/zephyr-ai-names-watson-pharmaceuticals-founder-dr-allen-chao-as-ceo-acquires-aster-insights-to-accelerate-cancer-drug-development 2025-08-26T13:54:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zephyr-ai-names-watson-pharmaceuticals-founder-dr-allen-chao-as-ceo-acquires-aster-insights-to-accelerate-cancer-drug-development 2025-08-26T13:54:30+00:00 hourly 0.9 https://trial.medpath.com/news/oxcia-s-oxc-101-receives-dual-orphan-drug-designation-from-ema-and-fda-for-acute-myeloid-leukemia-treatment 2025-08-26T13:54:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxcia-s-oxc-101-receives-dual-orphan-drug-designation-from-ema-and-fda-for-acute-myeloid-leukemia-treatment 2025-08-26T13:54:14+00:00 hourly 0.9 https://trial.medpath.com/news/new-clinical-trials-report-maps-global-landscape-for-autoimmune-hemolytic-anemia-research 2025-08-26T13:54:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-clinical-trials-report-maps-global-landscape-for-autoimmune-hemolytic-anemia-research 2025-08-26T13:54:12+00:00 hourly 0.9 https://trial.medpath.com/news/novel-panic-disorder-treatment-hb-1-enters-nationwide-clinical-trial-in-australia 2025-08-26T13:54:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-panic-disorder-treatment-hb-1-enters-nationwide-clinical-trial-in-australia 2025-08-26T13:54:09+00:00 hourly 0.9 https://trial.medpath.com/news/peach-bowl-donates-2-5-million-to-advance-18-pediatric-cancer-clinical-trials 2025-08-26T13:53:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peach-bowl-donates-2-5-million-to-advance-18-pediatric-cancer-clinical-trials 2025-08-26T13:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/abdera-therapeutics-reports-promising-early-data-for-dll3-targeted-radiopharmaceutical-abd-147-in-small-cell-lung-cancer 2025-08-26T12:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abdera-therapeutics-reports-promising-early-data-for-dll3-targeted-radiopharmaceutical-abd-147-in-small-cell-lung-cancer 2025-08-26T12:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/aditxt-s-adimune-advances-dna-based-immune-reprogramming-platform-with-96-patents-eyes-2026-clinical-trials 2025-08-26T09:55:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aditxt-s-adimune-advances-dna-based-immune-reprogramming-platform-with-96-patents-eyes-2026-clinical-trials 2025-08-26T09:55:59+00:00 hourly 0.9 https://trial.medpath.com/news/panntherapi-advances-pti5803-to-phase-iia-trial-for-drug-resistant-epilepsy 2025-08-26T09:54:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panntherapi-advances-pti5803-to-phase-iia-trial-for-drug-resistant-epilepsy 2025-08-26T09:54:42+00:00 hourly 0.9 https://trial.medpath.com/news/first-ever-clinical-trial-launches-to-test-afatinib-in-fanconi-anemia-associated-head-and-neck-cancer 2025-08-26T09:54:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-ever-clinical-trial-launches-to-test-afatinib-in-fanconi-anemia-associated-head-and-neck-cancer 2025-08-26T09:54:06+00:00 hourly 0.9 https://trial.medpath.com/news/basecare-medical-s-gems-culture-medium-receives-nmpa-approval-breaking-30-year-import-monopoly-in-china-s-ivf-market 2025-08-26T09:54:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basecare-medical-s-gems-culture-medium-receives-nmpa-approval-breaking-30-year-import-monopoly-in-china-s-ivf-market 2025-08-26T09:54:01+00:00 hourly 0.9 https://trial.medpath.com/news/global-analysis-reveals-critical-dosing-gaps-in-msc-derived-extracellular-vesicle-clinical-trials 2025-08-26T05:56:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-analysis-reveals-critical-dosing-gaps-in-msc-derived-extracellular-vesicle-clinical-trials 2025-08-26T05:56:03+00:00 hourly 0.9 https://trial.medpath.com/news/mascc-fellow-advocates-for-comprehensive-supportive-oncology-integration-in-cancer-centers 2025-08-26T03:04:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mascc-fellow-advocates-for-comprehensive-supportive-oncology-integration-in-cancer-centers 2025-08-26T03:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-vaccine-stocks-plummet-on-reports-of-potential-market-withdrawal 2025-08-26T01:56:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-vaccine-stocks-plummet-on-reports-of-potential-market-withdrawal 2025-08-26T01:56:02+00:00 hourly 0.9 https://trial.medpath.com/news/memgen-initiates-phase-1-combination-trial-of-mem-288-plus-docetaxel-for-advanced-nsclc 2025-08-26T01:55:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/memgen-initiates-phase-1-combination-trial-of-mem-288-plus-docetaxel-for-advanced-nsclc 2025-08-26T01:55:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-cleared-chemo-mouthpiece-reduces-oral-pain-by-46-and-opioid-use-by-68-in-pivotal-cancer-trial 2025-08-26T01:55:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-cleared-chemo-mouthpiece-reduces-oral-pain-by-46-and-opioid-use-by-68-in-pivotal-cancer-trial 2025-08-26T01:55:16+00:00 hourly 0.9 https://trial.medpath.com/news/vyome-therapeutics-goes-public-through-reverse-merger-advances-phase-ii-trial-for-rare-cancer-wound-condition 2025-08-26T01:53:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyome-therapeutics-goes-public-through-reverse-merger-advances-phase-ii-trial-for-rare-cancer-wound-condition 2025-08-26T01:53:48+00:00 hourly 0.9 https://trial.medpath.com/news/absci-strengthens-abs-201-hair-loss-program-with-leading-dermatology-experts 2025-08-26T01:53:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/absci-strengthens-abs-201-hair-loss-program-with-leading-dermatology-experts 2025-08-26T01:53:42+00:00 hourly 0.9 https://trial.medpath.com/news/uae-grants-world-s-first-approval-for-tolebrutinib-breakthrough-oral-treatment-for-progressive-multiple-sclerosis 2025-08-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uae-grants-world-s-first-approval-for-tolebrutinib-breakthrough-oral-treatment-for-progressive-multiple-sclerosis 2025-08-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rmtg-subsidiary-opens-advanced-cell-therapy-manufacturing-facility-in-mexico 2025-08-25T21:58:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rmtg-subsidiary-opens-advanced-cell-therapy-manufacturing-facility-in-mexico 2025-08-25T21:58:57+00:00 hourly 0.9 https://trial.medpath.com/news/propanc-biopharma-advances-novel-cancer-drug-prp-to-phase-1b-human-trials-following-4m-nasdaq-ipo 2025-08-25T21:58:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/propanc-biopharma-advances-novel-cancer-drug-prp-to-phase-1b-human-trials-following-4m-nasdaq-ipo 2025-08-25T21:58:52+00:00 hourly 0.9 https://trial.medpath.com/news/xeris-secures-additional-orange-book-patent-protection-for-recorlev-through-2040 2025-08-25T21:56:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xeris-secures-additional-orange-book-patent-protection-for-recorlev-through-2040 2025-08-25T21:56:30+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-to-present-cardiovascular-mortality-data-for-acoramidis-at-esc-congress-2025 2025-08-25T21:55:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-to-present-cardiovascular-mortality-data-for-acoramidis-at-esc-congress-2025 2025-08-25T21:55:24+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-reportedly-considering-covid-19-vaccine-withdrawal-within-months 2025-08-25T21:54:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-reportedly-considering-covid-19-vaccine-withdrawal-within-months 2025-08-25T21:54:26+00:00 hourly 0.9 https://trial.medpath.com/news/arnatar-therapeutics-emerges-with-52m-to-develop-first-in-class-rna-therapy-for-rare-genetic-disease 2025-08-25T21:53:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arnatar-therapeutics-emerges-with-52m-to-develop-first-in-class-rna-therapy-for-rare-genetic-disease 2025-08-25T21:53:55+00:00 hourly 0.9 https://trial.medpath.com/news/roche-breaks-ground-on-700m-north-carolina-manufacturing-facility-for-next-generation-obesity-treatments 2025-08-25T21:51:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-breaks-ground-on-700m-north-carolina-manufacturing-facility-for-next-generation-obesity-treatments 2025-08-25T21:51:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-form-483-to-novo-nordisk-s-bloomington-plant-over-contamination-and-safety-violations 2025-08-25T21:51:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-form-483-to-novo-nordisk-s-bloomington-plant-over-contamination-and-safety-violations 2025-08-25T21:51:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-repatha-indication-to-include-adults-at-high-risk-for-cardiovascular-events-without-prior-disease-diagnosis 2025-08-25T21:49:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-repatha-indication-to-include-adults-at-high-risk-for-cardiovascular-events-without-prior-disease-diagnosis 2025-08-25T21:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/mannkind-acquires-scpharmaceuticals-for-up-to-360m-to-expand-cardiorenal-portfolio 2025-08-25T18:00:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mannkind-acquires-scpharmaceuticals-for-up-to-360m-to-expand-cardiorenal-portfolio 2025-08-25T18:00:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-forzinity-for-barth-syndrome-following-congressional-advocacy 2025-08-25T17:59:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-forzinity-for-barth-syndrome-following-congressional-advocacy 2025-08-25T17:59:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-transitions-to-daily-adverse-event-reporting-for-drugs-and-biologics 2025-08-25T17:59:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-transitions-to-daily-adverse-event-reporting-for-drugs-and-biologics 2025-08-25T17:59:18+00:00 hourly 0.9 https://trial.medpath.com/news/catalyst-pharmaceuticals-secures-patent-protection-for-firdapse-until-2035-through-lupin-settlement 2025-08-25T17:58:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalyst-pharmaceuticals-secures-patent-protection-for-firdapse-until-2035-through-lupin-settlement 2025-08-25T17:58:40+00:00 hourly 0.9 https://trial.medpath.com/news/i-mab-strengthens-leadership-team-with-three-new-board-appointments-and-r-d-committee-formation 2025-08-25T17:58:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/i-mab-strengthens-leadership-team-with-three-new-board-appointments-and-r-d-committee-formation 2025-08-25T17:58:22+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-completes-phase-2b-trial-of-ameluz-for-moderate-to-severe-acne-treatment 2025-08-25T17:57:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofrontera-completes-phase-2b-trial-of-ameluz-for-moderate-to-severe-acne-treatment 2025-08-25T17:57:12+00:00 hourly 0.9 https://trial.medpath.com/news/immuneering-partners-with-lilly-for-phase-2-nsclc-combination-trial-testing-dual-mapk-pathway-blockade 2025-08-25T17:57:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneering-partners-with-lilly-for-phase-2-nsclc-combination-trial-testing-dual-mapk-pathway-blockade 2025-08-25T17:57:02+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-to-present-new-cardiovascular-data-at-esc-congress-2025-including-breakthrough-non-obstructive-hcm-trial-results 2025-08-25T17:56:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-to-present-new-cardiovascular-data-at-esc-congress-2025-including-breakthrough-non-obstructive-hcm-trial-results 2025-08-25T17:56:12+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-testing-shows-promise-for-faster-ivf-success-in-women-over-35-pilot-study-finds 2025-08-25T17:55:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-testing-shows-promise-for-faster-ivf-success-in-women-over-35-pilot-study-finds 2025-08-25T17:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-omidubicel-for-severe-aplastic-anemia-treatment 2025-08-25T17:53:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-omidubicel-for-severe-aplastic-anemia-treatment 2025-08-25T17:53:38+00:00 hourly 0.9 https://trial.medpath.com/news/amarin-to-present-new-reduce-it-analyses-and-epa-mechanistic-data-at-esc-congress-2025 2025-08-25T17:53:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amarin-to-present-new-reduce-it-analyses-and-epa-mechanistic-data-at-esc-congress-2025 2025-08-25T17:53:33+00:00 hourly 0.9 https://trial.medpath.com/news/arnatar-therapeutics-emerges-from-stealth-with-fda-orphan-drug-designation-for-art4-in-alagille-syndrome 2025-08-25T17:53:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arnatar-therapeutics-emerges-from-stealth-with-fda-orphan-drug-designation-for-art4-in-alagille-syndrome 2025-08-25T17:53:25+00:00 hourly 0.9 https://trial.medpath.com/news/danforth-advisors-acquires-pharmadirections-to-create-comprehensive-drug-development-platform 2025-08-25T17:52:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/danforth-advisors-acquires-pharmadirections-to-create-comprehensive-drug-development-platform 2025-08-25T17:52:22+00:00 hourly 0.9 https://trial.medpath.com/news/briacell-receives-2-million-nci-grant-to-advance-personalized-prostate-cancer-immunotherapy 2025-08-25T17:52:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/briacell-receives-2-million-nci-grant-to-advance-personalized-prostate-cancer-immunotherapy 2025-08-25T17:52:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-not-approvable-letter-for-envveno-medical-s-venovalve-shares-plummet-76 2025-08-25T17:50:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-not-approvable-letter-for-envveno-medical-s-venovalve-shares-plummet-76 2025-08-25T17:50:50+00:00 hourly 0.9 https://trial.medpath.com/news/pcm-trials-emvenio-research-and-clinical-trial-service-consolidate-under-emvenio-clinical-research-brand 2025-08-25T17:50:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pcm-trials-emvenio-research-and-clinical-trial-service-consolidate-under-emvenio-clinical-research-brand 2025-08-25T17:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/adva-biotechnology-and-autolomous-launch-digital-pioneer-program-to-transform-autologous-cell-therapy-manufacturing 2025-08-25T17:50:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adva-biotechnology-and-autolomous-launch-digital-pioneer-program-to-transform-autologous-cell-therapy-manufacturing 2025-08-25T17:50:01+00:00 hourly 0.9 https://trial.medpath.com/news/bio-libra-study-reveals-gender-disparities-in-cardiac-device-outcomes-for-non-ischemic-cardiomyopathy 2025-08-25T17:47:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-libra-study-reveals-gender-disparities-in-cardiac-device-outcomes-for-non-ischemic-cardiomyopathy 2025-08-25T17:47:58+00:00 hourly 0.9 https://trial.medpath.com/news/talphera-shares-surge-20-on-nephro-crrt-trial-enrollment-milestone 2025-08-25T17:47:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/talphera-shares-surge-20-on-nephro-crrt-trial-enrollment-milestone 2025-08-25T17:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/hereditary-angioedema-pipeline-shows-robust-growth-with-30-therapies-in-development-across-multiple-clinical-stages 2025-08-25T17:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hereditary-angioedema-pipeline-shows-robust-growth-with-30-therapies-in-development-across-multiple-clinical-stages 2025-08-25T17:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/vaxxas-secures-a-90-million-to-advance-needle-free-vaccine-delivery-technology-toward-market 2025-08-25T14:03:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxxas-secures-a-90-million-to-advance-needle-free-vaccine-delivery-technology-toward-market 2025-08-25T14:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/oryzon-receives-ema-approval-for-first-lsd1-inhibitor-trial-in-sickle-cell-disease 2025-08-25T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oryzon-receives-ema-approval-for-first-lsd1-inhibitor-trial-in-sickle-cell-disease 2025-08-25T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-stool-mrna-biomarkers-show-promise-for-non-invasive-colorectal-cancer-detection 2025-08-25T13:55:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-stool-mrna-biomarkers-show-promise-for-non-invasive-colorectal-cancer-detection 2025-08-25T13:55:22+00:00 hourly 0.9 https://trial.medpath.com/news/theravance-biopharma-completes-phase-3-enrollment-for-ampreloxetine-in-rare-neurological-disorder 2025-08-25T13:54:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theravance-biopharma-completes-phase-3-enrollment-for-ampreloxetine-in-rare-neurological-disorder 2025-08-25T13:54:54+00:00 hourly 0.9 https://trial.medpath.com/news/incyclix-bio-raises-11-25-million-to-advance-cdk2-inhibitor-inx-315-for-treatment-resistant-breast-and-ovarian-cancers 2025-08-25T13:54:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyclix-bio-raises-11-25-million-to-advance-cdk2-inhibitor-inx-315-for-treatment-resistant-breast-and-ovarian-cancers 2025-08-25T13:54:19+00:00 hourly 0.9 https://trial.medpath.com/news/akiram-s-targeted-radiotherapy-akir001-advances-to-next-phase-after-completing-first-patient-cohort-without-safety-concerns 2025-08-25T13:54:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akiram-s-targeted-radiotherapy-akir001-advances-to-next-phase-after-completing-first-patient-cohort-without-safety-concerns 2025-08-25T13:54:05+00:00 hourly 0.9 https://trial.medpath.com/news/proverum-raises-80-million-series-b-to-commercialize-minimally-invasive-bph-treatment 2025-08-25T13:53:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proverum-raises-80-million-series-b-to-commercialize-minimally-invasive-bph-treatment 2025-08-25T13:53:48+00:00 hourly 0.9 https://trial.medpath.com/news/wingor-biotechnology-secures-tens-of-millions-in-funding-to-advance-stem-cell-and-gene-therapy-pipeline 2025-08-25T13:53:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wingor-biotechnology-secures-tens-of-millions-in-funding-to-advance-stem-cell-and-gene-therapy-pipeline 2025-08-25T13:53:34+00:00 hourly 0.9 https://trial.medpath.com/news/organox-acquired-for-1-5-billion-in-one-of-uk-s-largest-medtech-exits 2025-08-25T13:53:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organox-acquired-for-1-5-billion-in-one-of-uk-s-largest-medtech-exits 2025-08-25T13:53:25+00:00 hourly 0.9 https://trial.medpath.com/news/royalty-pharma-acquires-950-million-imdelltra-royalty-rights-from-beone-medicines 2025-08-25T13:52:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/royalty-pharma-acquires-950-million-imdelltra-royalty-rights-from-beone-medicines 2025-08-25T13:52:13+00:00 hourly 0.9 https://trial.medpath.com/news/leads-biolabs-advances-first-in-china-gprc5d-t-cell-engager-lbl-034-to-phase-ii-trial 2025-08-25T13:51:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leads-biolabs-advances-first-in-china-gprc5d-t-cell-engager-lbl-034-to-phase-ii-trial 2025-08-25T13:51:43+00:00 hourly 0.9 https://trial.medpath.com/news/royalty-pharma-acquires-885-million-royalty-interest-in-amgen-s-imdelltra-for-small-cell-lung-cancer 2025-08-25T13:51:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/royalty-pharma-acquires-885-million-royalty-interest-in-amgen-s-imdelltra-for-small-cell-lung-cancer 2025-08-25T13:51:37+00:00 hourly 0.9 https://trial.medpath.com/news/dexa-psych-trial-investigates-dexamethasone-as-rapid-acting-depression-treatment 2025-08-25T13:51:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dexa-psych-trial-investigates-dexamethasone-as-rapid-acting-depression-treatment 2025-08-25T13:51:31+00:00 hourly 0.9 https://trial.medpath.com/news/oculis-strengthens-leadership-with-appointment-of-two-world-renowned-ophthalmology-experts-as-chief-medical-advisors 2025-08-25T13:50:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oculis-strengthens-leadership-with-appointment-of-two-world-renowned-ophthalmology-experts-as-chief-medical-advisors 2025-08-25T13:50:50+00:00 hourly 0.9 https://trial.medpath.com/news/lumateperone-shows-significant-efficacy-as-adjunctive-therapy-for-treatment-resistant-major-depression 2025-08-25T13:50:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumateperone-shows-significant-efficacy-as-adjunctive-therapy-for-treatment-resistant-major-depression 2025-08-25T13:50:39+00:00 hourly 0.9 https://trial.medpath.com/news/south-african-hiv-cure-trial-achieves-breakthrough-one-woman-may-be-cured-using-novel-kick-and-kill-strategy 2025-08-25T13:50:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-african-hiv-cure-trial-achieves-breakthrough-one-woman-may-be-cured-using-novel-kick-and-kill-strategy 2025-08-25T13:50:31+00:00 hourly 0.9 https://trial.medpath.com/news/gd2-targeting-car-t-cells-show-66-response-rate-in-high-risk-neuroblastoma-trial 2025-08-25T09:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gd2-targeting-car-t-cells-show-66-response-rate-in-high-risk-neuroblastoma-trial 2025-08-25T09:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-s-bexicaserin-shows-sustained-59-seizure-reduction-in-rare-epilepsy-extension-study 2025-08-25T09:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-s-bexicaserin-shows-sustained-59-seizure-reduction-in-rare-epilepsy-extension-study 2025-08-25T09:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/neuren-pharmaceuticals-launches-first-ever-phase-3-trial-for-phelan-mcdermid-syndrome 2025-08-25T09:22:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuren-pharmaceuticals-launches-first-ever-phase-3-trial-for-phelan-mcdermid-syndrome 2025-08-25T09:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-launches-first-pd-1-immunotherapy-and-parp-inhibitor-for-gynecological-cancers-in-india 2025-08-25T09:22:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-launches-first-pd-1-immunotherapy-and-parp-inhibitor-for-gynecological-cancers-in-india 2025-08-25T09:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/cambrex-expands-peptide-manufacturing-capabilities-with-20-facility-growth-in-massachusetts 2025-08-25T09:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambrex-expands-peptide-manufacturing-capabilities-with-20-facility-growth-in-massachusetts 2025-08-25T09:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/vyvgart-achieves-primary-endpoint-in-phase-3-trial-for-achr-ab-seronegative-myasthenia-gravis 2025-08-25T09:21:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyvgart-achieves-primary-endpoint-in-phase-3-trial-for-achr-ab-seronegative-myasthenia-gravis 2025-08-25T09:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-develop-first-human-stem-cell-derived-a10-dopamine-neurons-for-depression-treatment 2025-08-25T09:20:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-scientists-develop-first-human-stem-cell-derived-a10-dopamine-neurons-for-depression-treatment 2025-08-25T09:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/expecto-health-science-partners-with-vertispro-to-deploy-ai-driven-patient-recruitment-in-asia-pacific-clinical-trials 2025-08-25T09:20:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expecto-health-science-partners-with-vertispro-to-deploy-ai-driven-patient-recruitment-in-asia-pacific-clinical-trials 2025-08-25T09:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/pbac-rejects-pbs-listing-for-alzheimer-s-drug-donanemab-despite-clinical-need 2025-08-25T05:45:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pbac-rejects-pbs-listing-for-alzheimer-s-drug-donanemab-despite-clinical-need 2025-08-25T05:45:32+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-appoints-yajie-li-as-chief-medical-officer-to-advance-antibody-therapeutics-pipeline 2025-08-25T05:44:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harbour-biomed-appoints-yajie-li-as-chief-medical-officer-to-advance-antibody-therapeutics-pipeline 2025-08-25T05:44:58+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-shows-potential-survival-benefit-in-her2-positive-breast-cancer-patients 2025-08-25T01:03:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-shows-potential-survival-benefit-in-her2-positive-breast-cancer-patients 2025-08-25T01:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/legend-innovation-life-science-fund-commits-50-million-to-mid-atlantic-biotherapeutics-for-anti-aging-drug-development 2025-08-24T17:50:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/legend-innovation-life-science-fund-commits-50-million-to-mid-atlantic-biotherapeutics-for-anti-aging-drug-development 2025-08-24T17:50:29+00:00 hourly 0.9 https://trial.medpath.com/news/savara-to-present-phase-3-impala-2-trial-data-and-host-apap-symposium-at-ers-congress-2025 2025-08-24T17:50:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/savara-to-present-phase-3-impala-2-trial-data-and-host-apap-symposium-at-ers-congress-2025 2025-08-24T17:50:18+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-immunotherapy-strategies-repurposed-for-autoimmune-disease-treatment-show-promise-in-early-studies 2025-08-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-immunotherapy-strategies-repurposed-for-autoimmune-disease-treatment-show-promise-in-early-studies 2025-08-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/akums-drugs-partners-with-zambian-government-to-establish-50-million-pharmaceutical-manufacturing-facility 2025-08-24T13:34:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akums-drugs-partners-with-zambian-government-to-establish-50-million-pharmaceutical-manufacturing-facility 2025-08-24T13:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/stellate-ganglion-block-shows-promise-for-ptsd-treatment-with-68-78-success-rate-in-israel 2025-08-24T13:34:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stellate-ganglion-block-shows-promise-for-ptsd-treatment-with-68-78-success-rate-in-israel 2025-08-24T13:34:03+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-patients-show-strong-confidence-in-pharmacist-delivered-vaccines-despite-low-vaccination-rates 2025-08-24T03:05:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-patients-show-strong-confidence-in-pharmacist-delivered-vaccines-despite-low-vaccination-rates 2025-08-24T03:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-reveals-higher-infection-risk-with-ms-treatments-particularly-ocrelizumab 2025-08-24T03:04:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-reveals-higher-infection-risk-with-ms-treatments-particularly-ocrelizumab 2025-08-24T03:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/rasal2-variant-identified-as-novel-biomarker-for-anti-egfr-therapy-resistance-in-colorectal-cancer 2025-08-24T01:42:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rasal2-variant-identified-as-novel-biomarker-for-anti-egfr-therapy-resistance-in-colorectal-cancer 2025-08-24T01:42:06+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-therapeutics-refinances-700m-convertible-notes-to-strengthen-financial-position 2025-08-23T21:52:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-therapeutics-refinances-700m-convertible-notes-to-strengthen-financial-position 2025-08-23T21:52:31+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-advances-litifilimab-development-with-phase-3-extension-study-and-novel-drug-delivery-research-for-lupus-treatment 2025-08-23T21:49:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-advances-litifilimab-development-with-phase-3-extension-study-and-novel-drug-delivery-research-for-lupus-treatment 2025-08-23T21:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-s-anktiva-shows-promise-in-reversing-lymphopenia-in-advanced-lung-cancer-patients 2025-08-23T21:48:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitybio-s-anktiva-shows-promise-in-reversing-lymphopenia-in-advanced-lung-cancer-patients 2025-08-23T21:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/dynavax-technologies-z-1018-shingles-vaccine-shows-promise-in-phase-1-2-trial-with-improved-safety-profile 2025-08-23T21:48:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dynavax-technologies-z-1018-shingles-vaccine-shows-promise-in-phase-1-2-trial-with-improved-safety-profile 2025-08-23T21:48:45+00:00 hourly 0.9 https://trial.medpath.com/news/infliximab-biosimilar-ct-p13-demonstrates-safety-and-efficacy-in-real-world-rheumatoid-arthritis-treatment 2025-08-23T21:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infliximab-biosimilar-ct-p13-demonstrates-safety-and-efficacy-in-real-world-rheumatoid-arthritis-treatment 2025-08-23T21:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-issues-class-i-recall-of-carotid-wallstent-over-manufacturing-defect-linked-to-stroke-risk 2025-08-23T21:47:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-issues-class-i-recall-of-carotid-wallstent-over-manufacturing-defect-linked-to-stroke-risk 2025-08-23T21:47:28+00:00 hourly 0.9 https://trial.medpath.com/news/larkspur-biosciences-unveils-first-in-class-pip4k2c-degrader-lrk-4189-for-microsatellite-stable-colorectal-cancer 2025-08-23T17:53:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/larkspur-biosciences-unveils-first-in-class-pip4k2c-degrader-lrk-4189-for-microsatellite-stable-colorectal-cancer 2025-08-23T17:53:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-myopia-treatment-for-children-and-barth-syndrome-therapy-in-september-2025 2025-08-23T17:52:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-myopia-treatment-for-children-and-barth-syndrome-therapy-in-september-2025 2025-08-23T17:52:30+00:00 hourly 0.9 https://trial.medpath.com/news/pbac-rejects-multi-cancer-funding-model-for-keytruda-after-eight-years-of-deliberation 2025-08-23T17:49:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pbac-rejects-multi-cancer-funding-model-for-keytruda-after-eight-years-of-deliberation 2025-08-23T17:49:53+00:00 hourly 0.9 https://trial.medpath.com/news/defence-therapeutics-raises-up-to-1-2m-through-convertible-debenture-financing-to-advance-adc-platform 2025-08-23T17:48:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/defence-therapeutics-raises-up-to-1-2m-through-convertible-debenture-financing-to-advance-adc-platform 2025-08-23T17:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/agilent-technologies-receives-fda-approval-for-first-of-its-kind-colorectal-cancer-companion-diagnostic 2025-08-23T17:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agilent-technologies-receives-fda-approval-for-first-of-its-kind-colorectal-cancer-companion-diagnostic 2025-08-23T17:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/corbion-and-kuehnle-agrosystems-partner-to-develop-natural-astaxanthin-through-algae-fermentation 2025-08-23T13:46:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corbion-and-kuehnle-agrosystems-partner-to-develop-natural-astaxanthin-through-algae-fermentation 2025-08-23T13:46:29+00:00 hourly 0.9 https://trial.medpath.com/news/lb-pharmaceuticals-files-for-100-million-ipo-to-advance-schizophrenia-drug-lb-102-into-phase-iii 2025-08-23T13:46:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lb-pharmaceuticals-files-for-100-million-ipo-to-advance-schizophrenia-drug-lb-102-into-phase-iii 2025-08-23T13:46:27+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-acquires-paige-to-build-world-s-largest-oncology-foundation-model 2025-08-23T13:44:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-ai-acquires-paige-to-build-world-s-largest-oncology-foundation-model 2025-08-23T13:44:42+00:00 hourly 0.9 https://trial.medpath.com/news/anlon-healthcare-sets-ipo-price-band-at-86-91-per-share-for-121-crore-public-offering 2025-08-23T09:48:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anlon-healthcare-sets-ipo-price-band-at-86-91-per-share-for-121-crore-public-offering 2025-08-23T09:48:01+00:00 hourly 0.9 https://trial.medpath.com/news/fluorescent-probes-reveal-how-tirzepatide-targets-pancreas-and-brain-cells 2025-08-23T09:46:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fluorescent-probes-reveal-how-tirzepatide-targets-pancreas-and-brain-cells 2025-08-23T09:46:01+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-partners-with-philippines-to-establish-first-pharmaceutical-innovation-hub-in-peza-ecozone 2025-08-23T05:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-partners-with-philippines-to-establish-first-pharmaceutical-innovation-hub-in-peza-ecozone 2025-08-23T05:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/anti-pd-1-immunotherapy-shows-superior-outcomes-in-gastric-cancer-patients-with-chronic-hepatitis-b 2025-08-23T05:45:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anti-pd-1-immunotherapy-shows-superior-outcomes-in-gastric-cancer-patients-with-chronic-hepatitis-b 2025-08-23T05:45:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-blu-disposable-e-cigarette-marketing-application-over-dual-use-concerns 2025-08-23T05:44:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-blu-disposable-e-cigarette-marketing-application-over-dual-use-concerns 2025-08-23T05:44:58+00:00 hourly 0.9 https://trial.medpath.com/news/oncologists-explore-two-year-immunotherapy-duration-for-advanced-nsclc-to-balance-efficacy-and-financial-burden 2025-08-23T03:04:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncologists-explore-two-year-immunotherapy-duration-for-advanced-nsclc-to-balance-efficacy-and-financial-burden 2025-08-23T03:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/nci-funding-cut-forces-pediatric-brain-tumor-consortium-to-halt-clinical-trial-enrollment 2025-08-23T01:49:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nci-funding-cut-forces-pediatric-brain-tumor-consortium-to-halt-clinical-trial-enrollment 2025-08-23T01:49:28+00:00 hourly 0.9 https://trial.medpath.com/news/blossomhill-therapeutics-advances-egfr-mutant-nsclc-treatment-with-first-in-class-omni-egfr-inhibitor-bh-30643 2025-08-23T01:49:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blossomhill-therapeutics-advances-egfr-mutant-nsclc-treatment-with-first-in-class-omni-egfr-inhibitor-bh-30643 2025-08-23T01:49:21+00:00 hourly 0.9 https://trial.medpath.com/news/novel-basket-trial-design-targets-multiple-rare-fibrotic-skin-diseases-with-single-antifibrotic-therapy 2025-08-23T01:49:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-basket-trial-design-targets-multiple-rare-fibrotic-skin-diseases-with-single-antifibrotic-therapy 2025-08-23T01:49:14+00:00 hourly 0.9 https://trial.medpath.com/news/miami-valley-hospital-south-leads-global-bella-trial-testing-relacorilant-for-platinum-resistant-ovarian-cancer 2025-08-22T21:50:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/miami-valley-hospital-south-leads-global-bella-trial-testing-relacorilant-for-platinum-resistant-ovarian-cancer 2025-08-22T21:50:16+00:00 hourly 0.9 https://trial.medpath.com/news/aahi-partners-with-quratis-to-accelerate-global-vaccine-development-for-tuberculosis-malaria-and-hiv 2025-08-22T21:49:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aahi-partners-with-quratis-to-accelerate-global-vaccine-development-for-tuberculosis-malaria-and-hiv 2025-08-22T21:49:58+00:00 hourly 0.9 https://trial.medpath.com/news/gift-card-incentives-significantly-boost-low-income-participation-in-alzheimer-s-clinical-trial-registry 2025-08-22T21:48:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gift-card-incentives-significantly-boost-low-income-participation-in-alzheimer-s-clinical-trial-registry 2025-08-22T21:48:43+00:00 hourly 0.9 https://trial.medpath.com/news/indian-parliamentary-panel-calls-for-expanded-price-controls-on-cancer-drugs-including-immunotherapy-and-vaccines 2025-08-22T17:56:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-parliamentary-panel-calls-for-expanded-price-controls-on-cancer-drugs-including-immunotherapy-and-vaccines 2025-08-22T17:56:57+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-shows-promise-for-weight-loss-and-brown-adipose-tissue-activation-in-obesity-treatment 2025-08-22T17:53:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tirzepatide-shows-promise-for-weight-loss-and-brown-adipose-tissue-activation-in-obesity-treatment 2025-08-22T17:53:49+00:00 hourly 0.9 https://trial.medpath.com/news/cube-biotech-and-x-chem-breakthrough-enables-dna-encoded-library-screening-of-membrane-proteins 2025-08-22T17:53:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cube-biotech-and-x-chem-breakthrough-enables-dna-encoded-library-screening-of-membrane-proteins 2025-08-22T17:53:28+00:00 hourly 0.9 https://trial.medpath.com/news/cantargia-advances-nadunolimab-development-following-trifour-trial-results-secures-otsuka-partnership-for-can10-program 2025-08-22T17:53:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cantargia-advances-nadunolimab-development-following-trifour-trial-results-secures-otsuka-partnership-for-can10-program 2025-08-22T17:53:26+00:00 hourly 0.9 https://trial.medpath.com/news/lighthouse-pharmaceuticals-secures-49-2-million-nih-grant-for-novel-alzheimer-s-disease-treatment-targeting-bacterial-infection 2025-08-22T17:53:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lighthouse-pharmaceuticals-secures-49-2-million-nih-grant-for-novel-alzheimer-s-disease-treatment-targeting-bacterial-infection 2025-08-22T17:53:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-delays-gene-therapy-approval-for-sanfilippo-syndrome-until-2026-affecting-young-patients 2025-08-22T17:52:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-delays-gene-therapy-approval-for-sanfilippo-syndrome-until-2026-affecting-young-patients 2025-08-22T17:52:20+00:00 hourly 0.9 https://trial.medpath.com/news/yale-researchers-repurpose-cancer-drug-erlotinib-for-rare-genetic-skin-disorder 2025-08-22T17:52:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-researchers-repurpose-cancer-drug-erlotinib-for-rare-genetic-skin-disorder 2025-08-22T17:52:07+00:00 hourly 0.9 https://trial.medpath.com/news/jyong-biotech-s-botreso-r-shows-promising-phase-iii-results-for-benign-prostatic-hyperplasia-treatment 2025-08-22T17:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jyong-biotech-s-botreso-r-shows-promising-phase-iii-results-for-benign-prostatic-hyperplasia-treatment 2025-08-22T17:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/ten-year-study-confirms-long-term-safety-of-biosimilar-filgrastim-in-healthy-stem-cell-donors 2025-08-22T17:51:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ten-year-study-confirms-long-term-safety-of-biosimilar-filgrastim-in-healthy-stem-cell-donors 2025-08-22T17:51:57+00:00 hourly 0.9 https://trial.medpath.com/news/optimized-drug-treatment-reduces-mortality-in-acute-type-a-aortic-dissection-patients 2025-08-22T17:51:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optimized-drug-treatment-reduces-mortality-in-acute-type-a-aortic-dissection-patients 2025-08-22T17:51:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-cancels-advisory-committee-meeting-for-biohaven-s-troriluzole-signaling-potential-regulatory-clarity 2025-08-22T17:49:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-cancels-advisory-committee-meeting-for-biohaven-s-troriluzole-signaling-potential-regulatory-clarity 2025-08-22T17:49:41+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-identify-protective-antibodies-against-strep-a-paving-way-for-life-saving-vaccine 2025-08-22T13:24:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-identify-protective-antibodies-against-strep-a-paving-way-for-life-saving-vaccine 2025-08-22T13:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-raises-57-5-million-to-advance-monoclonal-antibody-pipeline-targeting-rsv-measles-and-long-covid 2025-08-22T13:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivyd-raises-57-5-million-to-advance-monoclonal-antibody-pipeline-targeting-rsv-measles-and-long-covid 2025-08-22T13:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-launch-human-challenge-trial-to-accelerate-strep-a-vaccine-development 2025-08-22T13:20:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-researchers-launch-human-challenge-trial-to-accelerate-strep-a-vaccine-development 2025-08-22T13:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/esaote-s-mylab-a50-and-a70-ultrasound-systems-receive-fda-approval-for-us-market 2025-08-22T13:18:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esaote-s-mylab-a50-and-a70-ultrasound-systems-receive-fda-approval-for-us-market 2025-08-22T13:18:18+00:00 hourly 0.9 https://trial.medpath.com/news/valitor-s-vltr-559-shows-favorable-safety-profile-in-preclinical-studies-for-twice-yearly-wet-amd-treatment 2025-08-22T10:00:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valitor-s-vltr-559-shows-favorable-safety-profile-in-preclinical-studies-for-twice-yearly-wet-amd-treatment 2025-08-22T10:00:47+00:00 hourly 0.9 https://trial.medpath.com/news/lupus-nephritis-pipeline-shows-strong-activity-with-35-companies-developing-40-investigational-therapies 2025-08-22T09:55:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupus-nephritis-pipeline-shows-strong-activity-with-35-companies-developing-40-investigational-therapies 2025-08-22T09:55:12+00:00 hourly 0.9 https://trial.medpath.com/news/nugen-medical-devices-develops-next-generation-needle-free-injection-system-with-internal-cartridge-technology 2025-08-22T09:53:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nugen-medical-devices-develops-next-generation-needle-free-injection-system-with-internal-cartridge-technology 2025-08-22T09:53:10+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-companies-develop-glp-1-implant-for-pet-obesity-targeting-2028-market-launch 2025-08-22T07:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-companies-develop-glp-1-implant-for-pet-obesity-targeting-2028-market-launch 2025-08-22T07:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/vaginal-estrogen-tablets-show-no-increased-stroke-risk-for-postmenopausal-women-with-prior-stroke-history 2025-08-22T02:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaginal-estrogen-tablets-show-no-increased-stroke-risk-for-postmenopausal-women-with-prior-stroke-history 2025-08-22T02:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/artrya-receives-fda-clearance-for-ai-powered-coronary-plaque-detection-module-expands-us-revenue-opportunity 2025-08-22T02:04:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artrya-receives-fda-clearance-for-ai-powered-coronary-plaque-detection-module-expands-us-revenue-opportunity 2025-08-22T02:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/cyclophilin-inhibitor-shows-promise-for-reversing-alcohol-related-liver-fibrosis-in-human-tissue-models 2025-08-22T02:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyclophilin-inhibitor-shows-promise-for-reversing-alcohol-related-liver-fibrosis-in-human-tissue-models 2025-08-22T02:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/adalimumab-increases-infection-risk-53-in-hidradenitis-suppurativa-patients-compared-to-psoriasis 2025-08-22T02:04:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adalimumab-increases-infection-risk-53-in-hidradenitis-suppurativa-patients-compared-to-psoriasis 2025-08-22T02:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/oral-testosterone-undecanoate-shows-superior-sexual-function-improvements-in-phase-3-trial 2025-08-22T02:03:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-testosterone-undecanoate-shows-superior-sexual-function-improvements-in-phase-3-trial 2025-08-22T02:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-royalty-acquires-mural-oncology-for-36-2-million-in-strategic-biotech-consolidation 2025-08-22T02:02:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xoma-royalty-acquires-mural-oncology-for-36-2-million-in-strategic-biotech-consolidation 2025-08-22T02:02:46+00:00 hourly 0.9 https://trial.medpath.com/news/rambam-hospital-pioneers-crispr-gene-therapy-trial-for-cardiac-amyloidosis 2025-08-22T02:02:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rambam-hospital-pioneers-crispr-gene-therapy-trial-for-cardiac-amyloidosis 2025-08-22T02:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/fda-inspection-reveals-contamination-issues-at-novo-nordisk-s-indiana-manufacturing-plant 2025-08-22T02:02:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-inspection-reveals-contamination-issues-at-novo-nordisk-s-indiana-manufacturing-plant 2025-08-22T02:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-appeals-to-fda-commissioner-makary-over-generic-hetlioz-approvals-following-court-victory 2025-08-22T02:00:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-pharmaceuticals-appeals-to-fda-commissioner-makary-over-generic-hetlioz-approvals-following-court-victory 2025-08-22T02:00:22+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-s-bnt113-mrna-cancer-vaccine-advances-in-phase-2-trial-for-hpv-head-and-neck-cancer 2025-08-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-s-bnt113-mrna-cancer-vaccine-advances-in-phase-2-trial-for-hpv-head-and-neck-cancer 2025-08-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/thryv-therapeutics-unveils-breakthrough-sgk1-inhibitor-data-for-heart-failure-and-long-qt-syndrome-at-esc-congress-2025 2025-08-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thryv-therapeutics-unveils-breakthrough-sgk1-inhibitor-data-for-heart-failure-and-long-qt-syndrome-at-esc-congress-2025 2025-08-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-opens-192-5m-manufacturing-facility-to-boost-us-laboratory-supply-chain 2025-08-21T21:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-opens-192-5m-manufacturing-facility-to-boost-us-laboratory-supply-chain 2025-08-21T21:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/ibt-s-ibp-9414-shows-27-reduction-in-death-risk-for-premature-infants-with-nec-in-phase-iii-trial 2025-08-21T20:55:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibt-s-ibp-9414-shows-27-reduction-in-death-risk-for-premature-infants-with-nec-in-phase-iii-trial 2025-08-21T20:55:46+00:00 hourly 0.9 https://trial.medpath.com/news/pneumococcal-disease-pipeline-shows-strong-growth-with-20-therapies-in-development 2025-08-21T20:46:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pneumococcal-disease-pipeline-shows-strong-growth-with-20-therapies-in-development 2025-08-21T20:46:54+00:00 hourly 0.9 https://trial.medpath.com/news/krystal-biotech-prioritizes-inhaled-kb707-for-nsclc-treatment-secures-fda-end-of-phase-2-meeting 2025-08-21T20:43:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/krystal-biotech-prioritizes-inhaled-kb707-for-nsclc-treatment-secures-fda-end-of-phase-2-meeting 2025-08-21T20:43:09+00:00 hourly 0.9 https://trial.medpath.com/news/robotic-manufacturing-achieves-74-cost-reduction-in-cell-therapy-production 2025-08-21T20:41:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robotic-manufacturing-achieves-74-cost-reduction-in-cell-therapy-production 2025-08-21T20:41:53+00:00 hourly 0.9 https://trial.medpath.com/news/smsbiotech-launches-first-in-human-phase-1-trial-of-novel-stem-cell-therapy-for-copd 2025-08-21T20:41:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smsbiotech-launches-first-in-human-phase-1-trial-of-novel-stem-cell-therapy-for-copd 2025-08-21T20:41:38+00:00 hourly 0.9 https://trial.medpath.com/news/bispecific-innate-cell-engager-afm28-shows-promise-against-leukemic-stem-cells-in-aml-and-mds 2025-08-21T20:40:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bispecific-innate-cell-engager-afm28-shows-promise-against-leukemic-stem-cells-in-aml-and-mds 2025-08-21T20:40:07+00:00 hourly 0.9 https://trial.medpath.com/news/european-scientists-propose-alliance-to-advance-proximity-induced-drug-development-for-undruggable-targets 2025-08-21T20:26:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-scientists-propose-alliance-to-advance-proximity-induced-drug-development-for-undruggable-targets 2025-08-21T20:26:10+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-commits-2-billion-to-north-carolina-manufacturing-facility-in-major-us-investment-push 2025-08-21T20:23:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-commits-2-billion-to-north-carolina-manufacturing-facility-in-major-us-investment-push 2025-08-21T20:23:22+00:00 hourly 0.9 https://trial.medpath.com/news/realta-life-sciences-receives-european-orphan-drug-designation-for-graft-versus-host-disease-treatment 2025-08-21T20:22:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/realta-life-sciences-receives-european-orphan-drug-designation-for-graft-versus-host-disease-treatment 2025-08-21T20:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/protagenic-therapeutics-advances-novel-tcap-based-therapy-pt00114-into-multiple-dose-phase-1-trial-for-stress-related-disorders 2025-08-21T20:19:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagenic-therapeutics-advances-novel-tcap-based-therapy-pt00114-into-multiple-dose-phase-1-trial-for-stress-related-disorders 2025-08-21T20:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/septerna-initiates-first-in-human-trial-of-sep-631-for-chronic-spontaneous-urticaria 2025-08-21T20:18:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/septerna-initiates-first-in-human-trial-of-sep-631-for-chronic-spontaneous-urticaria 2025-08-21T20:18:07+00:00 hourly 0.9 https://trial.medpath.com/news/dynavax-s-z-1018-shingles-vaccine-matches-gsk-s-shingrix-efficacy-with-superior-tolerability-in-phase-i-ii-trial 2025-08-21T20:17:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dynavax-s-z-1018-shingles-vaccine-matches-gsk-s-shingrix-efficacy-with-superior-tolerability-in-phase-i-ii-trial 2025-08-21T20:17:51+00:00 hourly 0.9 https://trial.medpath.com/news/kite-acquires-interius-biotherapeutics-for-350m-to-advance-in-vivo-car-t-platform 2025-08-21T20:17:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kite-acquires-interius-biotherapeutics-for-350m-to-advance-in-vivo-car-t-platform 2025-08-21T20:17:42+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-secures-pan-canadian-agreement-for-leqvio-access-in-familial-hypercholesterolemia 2025-08-21T20:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-secures-pan-canadian-agreement-for-leqvio-access-in-familial-hypercholesterolemia 2025-08-21T20:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-crinetics-atumelnant-for-congenital-adrenal-hyperplasia-treatment 2025-08-21T20:09:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-crinetics-atumelnant-for-congenital-adrenal-hyperplasia-treatment 2025-08-21T20:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/zeiss-receives-ce-mark-approval-for-ai-powered-cirrus-pathfinder-oct-assessment-tool 2025-08-21T20:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeiss-receives-ce-mark-approval-for-ai-powered-cirrus-pathfinder-oct-assessment-tool 2025-08-21T20:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/andelyn-biosciences-partners-with-amplo-biotechnology-to-advance-aav-gene-therapies-for-neuromuscular-junction-disorders 2025-08-21T20:05:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andelyn-biosciences-partners-with-amplo-biotechnology-to-advance-aav-gene-therapies-for-neuromuscular-junction-disorders 2025-08-21T20:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/scilex-subsidiary-semnur-secures-20-million-funding-for-sp-102-phase-3-trial-in-sciatica-treatment 2025-08-21T20:04:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scilex-subsidiary-semnur-secures-20-million-funding-for-sp-102-phase-3-trial-in-sciatica-treatment 2025-08-21T20:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/catheter-precision-initiates-locket-compare-study-to-evaluate-safety-of-external-suture-retention-device 2025-08-21T20:03:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catheter-precision-initiates-locket-compare-study-to-evaluate-safety-of-external-suture-retention-device 2025-08-21T20:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/remote-weight-loss-intervention-shows-significant-success-in-breast-cancer-survivors-at-one-year-mark 2025-08-21T20:02:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remote-weight-loss-intervention-shows-significant-success-in-breast-cancer-survivors-at-one-year-mark 2025-08-21T20:02:11+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-anti-mouse-pd-1-agonist-antibodies-that-inhibit-t-cell-activation 2025-08-21T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-identify-anti-mouse-pd-1-agonist-antibodies-that-inhibit-t-cell-activation 2025-08-21T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-commits-55-billion-to-u-s-manufacturing-expansion-in-strategic-reshoring-initiative 2025-08-21T15:02:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-commits-55-billion-to-u-s-manufacturing-expansion-in-strategic-reshoring-initiative 2025-08-21T15:02:12+00:00 hourly 0.9 https://trial.medpath.com/news/mendus-expands-vididencel-clinical-strategy-across-aml-risk-categories-and-into-chronic-myeloid-leukemia 2025-08-21T15:00:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mendus-expands-vididencel-clinical-strategy-across-aml-risk-categories-and-into-chronic-myeloid-leukemia 2025-08-21T15:00:34+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-pharmaceutical-explores-india-for-global-clinical-trials-to-accelerate-drug-launches 2025-08-21T14:59:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-pharmaceutical-explores-india-for-global-clinical-trials-to-accelerate-drug-launches 2025-08-21T14:59:57+00:00 hourly 0.9 https://trial.medpath.com/news/strand-therapeutics-appoints-cancer-immunotherapy-pioneer-dr-jason-luke-as-chief-medical-officer 2025-08-21T14:59:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strand-therapeutics-appoints-cancer-immunotherapy-pioneer-dr-jason-luke-as-chief-medical-officer 2025-08-21T14:59:36+00:00 hourly 0.9 https://trial.medpath.com/news/gist-treatment-pipeline-shows-robust-activity-with-28-therapies-in-development-across-multiple-clinical-phases 2025-08-21T14:58:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gist-treatment-pipeline-shows-robust-activity-with-28-therapies-in-development-across-multiple-clinical-phases 2025-08-21T14:58:30+00:00 hourly 0.9 https://trial.medpath.com/news/oncozenge-secures-funding-for-european-phase-iii-cancer-trial-as-alzinova-advances-alzheimer-s-program 2025-08-21T14:57:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncozenge-secures-funding-for-european-phase-iii-cancer-trial-as-alzinova-advances-alzheimer-s-program 2025-08-21T14:57:12+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-partners-with-anges-for-hgf-gene-therapy-manufacturing-ahead-of-fda-filing 2025-08-21T14:56:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-partners-with-anges-for-hgf-gene-therapy-manufacturing-ahead-of-fda-filing 2025-08-21T14:56:32+00:00 hourly 0.9 https://trial.medpath.com/news/krystal-biotech-halts-melanoma-study-of-kb707-following-fda-rejection-of-similar-viral-immunotherapy 2025-08-21T14:55:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/krystal-biotech-halts-melanoma-study-of-kb707-following-fda-rejection-of-similar-viral-immunotherapy 2025-08-21T14:55:53+00:00 hourly 0.9 https://trial.medpath.com/news/nuwellis-receives-fda-510-k-clearance-for-extended-length-catheter-to-enhance-fluid-management-platform 2025-08-21T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuwellis-receives-fda-510-k-clearance-for-extended-length-catheter-to-enhance-fluid-management-platform 2025-08-21T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/fat-trapping-microbeads-show-promise-for-drug-free-weight-loss-in-preclinical-study 2025-08-21T10:38:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fat-trapping-microbeads-show-promise-for-drug-free-weight-loss-in-preclinical-study 2025-08-21T10:38:27+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-gene-therapy-for-p47-chronic-granulomatous-disease-shows-success-in-teenage-patient 2025-08-21T09:50:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-gene-therapy-for-p47-chronic-granulomatous-disease-shows-success-in-teenage-patient 2025-08-21T09:50:13+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-partners-appoints-martin-steegmaier-as-chief-scientific-officer-to-advance-darpin-therapeutics-pipeline 2025-08-21T09:50:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-partners-appoints-martin-steegmaier-as-chief-scientific-officer-to-advance-darpin-therapeutics-pipeline 2025-08-21T09:50:08+00:00 hourly 0.9 https://trial.medpath.com/news/jak-inhibitor-pipeline-shows-robust-growth-with-55-therapies-in-development-across-multiple-therapeutic-areas 2025-08-21T08:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jak-inhibitor-pipeline-shows-robust-growth-with-55-therapies-in-development-across-multiple-therapeutic-areas 2025-08-21T08:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/cvs-health-declines-coverage-for-gilead-s-hiv-prevention-drug-yeztugo-despite-99-9-efficacy 2025-08-21T04:48:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cvs-health-declines-coverage-for-gilead-s-hiv-prevention-drug-yeztugo-despite-99-9-efficacy 2025-08-21T04:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/trethera-secures-5-3-million-in-nih-funding-to-advance-first-in-class-dck-inhibitor-tre-515-across-cancer-and-autoimmune-indications 2025-08-21T04:45:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trethera-secures-5-3-million-in-nih-funding-to-advance-first-in-class-dck-inhibitor-tre-515-across-cancer-and-autoimmune-indications 2025-08-21T04:45:23+00:00 hourly 0.9 https://trial.medpath.com/news/paroxysmal-nocturnal-hemoglobinuria-pipeline-shows-robust-development-with-25-therapies-from-leading-pharmaceutical-companies 2025-08-21T04:44:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paroxysmal-nocturnal-hemoglobinuria-pipeline-shows-robust-development-with-25-therapies-from-leading-pharmaceutical-companies 2025-08-21T04:44:53+00:00 hourly 0.9 https://trial.medpath.com/news/esophageal-cancer-pipeline-shows-promise-with-100-therapies-in-development-across-80-companies 2025-08-21T04:44:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esophageal-cancer-pipeline-shows-promise-with-100-therapies-in-development-across-80-companies 2025-08-21T04:44:39+00:00 hourly 0.9 https://trial.medpath.com/news/tryptamine-therapeutics-partners-with-imperial-college-to-develop-eeg-based-biomarker-for-precision-psychedelic-therapy 2025-08-21T04:43:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tryptamine-therapeutics-partners-with-imperial-college-to-develop-eeg-based-biomarker-for-precision-psychedelic-therapy 2025-08-21T04:43:52+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-reports-strong-growth-with-93-increase-in-olverembatinib-sales-and-historic-lisaftoclax-approval 2025-08-21T04:43:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascentage-pharma-reports-strong-growth-with-93-increase-in-olverembatinib-sales-and-historic-lisaftoclax-approval 2025-08-21T04:43:37+00:00 hourly 0.9 https://trial.medpath.com/news/equitable-access-to-biomarker-testing-and-perioperative-treatment-critical-for-nsclc-outcomes 2025-08-21T04:39:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/equitable-access-to-biomarker-testing-and-perioperative-treatment-critical-for-nsclc-outcomes 2025-08-21T04:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-royalty-acquires-mural-oncology-for-35-2-38-8m-in-latest-biotech-liquidation-deal 2025-08-21T03:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xoma-royalty-acquires-mural-oncology-for-35-2-38-8m-in-latest-biotech-liquidation-deal 2025-08-21T03:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/steel-therapeutics-advances-fizurex-topical-wipe-for-anal-fissures-with-2m-funding-and-pivotal-toxicology-study 2025-08-21T03:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/steel-therapeutics-advances-fizurex-topical-wipe-for-anal-fissures-with-2m-funding-and-pivotal-toxicology-study 2025-08-21T03:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/kromatid-secures-8-million-series-c-to-advance-genomic-analysis-platform-for-gene-and-cell-therapy 2025-08-21T03:07:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kromatid-secures-8-million-series-c-to-advance-genomic-analysis-platform-for-gene-and-cell-therapy 2025-08-21T03:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/savara-s-inhaled-molgramostim-shows-9-8-lung-function-improvement-in-phase-3-autoimmune-pap-trial 2025-08-21T03:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/savara-s-inhaled-molgramostim-shows-9-8-lung-function-improvement-in-phase-3-autoimmune-pap-trial 2025-08-21T03:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/chempartner-establishes-boston-r-d-center-to-strengthen-u-s-biopharma-partnerships 2025-08-21T03:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chempartner-establishes-boston-r-d-center-to-strengthen-u-s-biopharma-partnerships 2025-08-21T03:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/primary-hyperoxaluria-pipeline-shows-promise-with-6-therapies-in-development-as-gene-editing-advances 2025-08-21T03:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/primary-hyperoxaluria-pipeline-shows-promise-with-6-therapies-in-development-as-gene-editing-advances 2025-08-21T03:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-epilepsy-drug-z944-reverses-autism-like-behaviors-in-preclinical-study 2025-08-21T03:05:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-epilepsy-drug-z944-reverses-autism-like-behaviors-in-preclinical-study 2025-08-21T03:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/hdac-inhibitors-market-projected-to-surge-through-2034-as-next-generation-cancer-therapies-advance-in-clinical-trials 2025-08-21T03:05:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hdac-inhibitors-market-projected-to-surge-through-2034-as-next-generation-cancer-therapies-advance-in-clinical-trials 2025-08-21T03:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/greenwich-lifesciences-advances-phase-iii-flamingo-01-trial-for-her2-positive-breast-cancer-immunotherapy 2025-08-21T03:05:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenwich-lifesciences-advances-phase-iii-flamingo-01-trial-for-her2-positive-breast-cancer-immunotherapy 2025-08-21T03:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/healthcare-coalition-urges-cms-to-accelerate-medicare-coverage-for-breakthrough-medical-devices 2025-08-21T03:04:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healthcare-coalition-urges-cms-to-accelerate-medicare-coverage-for-breakthrough-medical-devices 2025-08-21T03:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-approves-breakthrough-bladder-cancer-treatment-that-doubles-survival-rates 2025-08-21T03:04:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-approves-breakthrough-bladder-cancer-treatment-that-doubles-survival-rates 2025-08-21T03:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-screen-identifies-gator1-complex-as-key-suppressor-of-myc-driven-lymphomas-with-therapeutic-implications 2025-08-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-screen-identifies-gator1-complex-as-key-suppressor-of-myc-driven-lymphomas-with-therapeutic-implications 2025-08-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/accelerated-manufacturing-platform-enables-rapid-hiv-vaccine-production-for-clinical-trials 2025-08-20T21:14:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accelerated-manufacturing-platform-enables-rapid-hiv-vaccine-production-for-clinical-trials 2025-08-20T21:14:46+00:00 hourly 0.9 https://trial.medpath.com/news/trehalose-loaded-lipid-nanoparticles-enhance-mrna-vaccine-stability-and-bridge-in-vitro-in-vivo-efficacy-gap 2025-08-20T21:14:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trehalose-loaded-lipid-nanoparticles-enhance-mrna-vaccine-stability-and-bridge-in-vitro-in-vivo-efficacy-gap 2025-08-20T21:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-completes-phase-i-trial-for-investigational-oral-drug-nnc0560-0004 2025-08-20T21:12:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-completes-phase-i-trial-for-investigational-oral-drug-nnc0560-0004 2025-08-20T21:12:58+00:00 hourly 0.9 https://trial.medpath.com/news/elysium-therapeutics-advances-novel-fentanyl-overdose-rescue-therapy-following-fda-pre-ind-meeting 2025-08-20T21:12:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elysium-therapeutics-advances-novel-fentanyl-overdose-rescue-therapy-following-fda-pre-ind-meeting 2025-08-20T21:12:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-upholds-rejection-of-envveno-s-venovalve-for-chronic-venous-insufficiency-treatment 2025-08-20T21:09:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-upholds-rejection-of-envveno-s-venovalve-for-chronic-venous-insufficiency-treatment 2025-08-20T21:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-research-demonstrates-ultra-high-concentration-biologic-delivery-via-subcutaneous-injection 2025-08-20T21:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-research-demonstrates-ultra-high-concentration-biologic-delivery-via-subcutaneous-injection 2025-08-20T21:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/evolus-submits-fda-application-for-evolysse-sculpt-mid-face-dermal-filler 2025-08-20T21:08:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolus-submits-fda-application-for-evolysse-sculpt-mid-face-dermal-filler 2025-08-20T21:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/rituximab-outperforms-cladribine-in-real-world-multiple-sclerosis-study 2025-08-20T21:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rituximab-outperforms-cladribine-in-real-world-multiple-sclerosis-study 2025-08-20T21:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/enanta-pharmaceuticals-challenges-pfizer-s-paxlovid-in-european-patent-court-seeking-damages-for-antiviral-ip-infringement 2025-08-20T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enanta-pharmaceuticals-challenges-pfizer-s-paxlovid-in-european-patent-court-seeking-damages-for-antiviral-ip-infringement 2025-08-20T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-receives-mixed-cdsco-decisions-on-dermatology-drug-trials 2025-08-20T17:19:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-receives-mixed-cdsco-decisions-on-dermatology-drug-trials 2025-08-20T17:19:54+00:00 hourly 0.9 https://trial.medpath.com/news/tivic-health-advances-entolimod-development-with-two-fda-investigational-new-drug-applications 2025-08-20T17:17:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tivic-health-advances-entolimod-development-with-two-fda-investigational-new-drug-applications 2025-08-20T17:17:52+00:00 hourly 0.9 https://trial.medpath.com/news/former-fda-commissioner-stephen-hahn-named-ceo-of-radiopharmaceuticals-cdmo-nucleus-radiopharma 2025-08-20T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-fda-commissioner-stephen-hahn-named-ceo-of-radiopharmaceuticals-cdmo-nucleus-radiopharma 2025-08-20T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-senate-backs-expanded-clinical-trial-endpoints-for-alcohol-use-disorder-boosting-adial-s-ad04-development-strategy 2025-08-20T17:16:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-senate-backs-expanded-clinical-trial-endpoints-for-alcohol-use-disorder-boosting-adial-s-ad04-development-strategy 2025-08-20T17:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/jazz-pharmaceuticals-acquires-exclusive-rights-to-epilepsy-drug-san2355-in-42-5m-deal 2025-08-20T17:15:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-acquires-exclusive-rights-to-epilepsy-drug-san2355-in-42-5m-deal 2025-08-20T17:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-digital-transformation-slashes-cell-and-gene-therapy-approval-times-by-82 2025-08-20T17:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-digital-transformation-slashes-cell-and-gene-therapy-approval-times-by-82 2025-08-20T17:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/keros-therapeutics-receives-fda-orphan-drug-designation-for-ker-065-in-duchenne-muscular-dystrophy 2025-08-20T17:14:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keros-therapeutics-receives-fda-orphan-drug-designation-for-ker-065-in-duchenne-muscular-dystrophy 2025-08-20T17:14:08+00:00 hourly 0.9 https://trial.medpath.com/news/ginkgo-bioworks-partners-with-inductive-bio-and-tangible-scientific-to-launch-ai-driven-drug-discovery-platform 2025-08-20T17:14:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ginkgo-bioworks-partners-with-inductive-bio-and-tangible-scientific-to-launch-ai-driven-drug-discovery-platform 2025-08-20T17:14:05+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-you-raises-5m-series-a-to-scale-multi-omic-predictive-health-platform 2025-08-20T17:13:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-you-raises-5m-series-a-to-scale-multi-omic-predictive-health-platform 2025-08-20T17:13:28+00:00 hourly 0.9 https://trial.medpath.com/news/bioskryb-genomics-secures-exclusive-license-for-single-cell-dna-methylation-and-variant-analysis-technology 2025-08-20T17:13:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioskryb-genomics-secures-exclusive-license-for-single-cell-dna-methylation-and-variant-analysis-technology 2025-08-20T17:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/scipher-medicine-launches-ai-platform-to-predict-clinical-trial-failures-with-near-perfect-accuracy 2025-08-20T17:13:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scipher-medicine-launches-ai-platform-to-predict-clinical-trial-failures-with-near-perfect-accuracy 2025-08-20T17:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/tharimmune-stock-surges-60-following-fda-fast-track-designation-and-5-47m-equity-raise 2025-08-20T17:13:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tharimmune-stock-surges-60-following-fda-fast-track-designation-and-5-47m-equity-raise 2025-08-20T17:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/agilent-s-mmr-ihc-panel-pharmdx-receives-fda-approval-as-companion-diagnostic-for-colorectal-cancer-immunotherapy 2025-08-20T17:13:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agilent-s-mmr-ihc-panel-pharmdx-receives-fda-approval-as-companion-diagnostic-for-colorectal-cancer-immunotherapy 2025-08-20T17:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-researchers-launch-phase-1-trial-of-novel-cyclin-inhibitor-for-small-cell-lung-cancer 2025-08-20T17:11:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-researchers-launch-phase-1-trial-of-novel-cyclin-inhibitor-for-small-cell-lung-cancer 2025-08-20T17:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-neuroscience-chief-anne-white-to-retire-after-leading-alzheimer-s-drug-launch 2025-08-20T17:11:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-neuroscience-chief-anne-white-to-retire-after-leading-alzheimer-s-drug-launch 2025-08-20T17:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/first-nations-launch-comparative-drug-trial-to-combat-psoroptic-mange-in-declining-bighorn-sheep-population 2025-08-20T17:10:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-nations-launch-comparative-drug-trial-to-combat-psoroptic-mange-in-declining-bighorn-sheep-population 2025-08-20T17:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/illuminated-extractors-secures-patent-for-revolutionary-cryogenic-refrigeration-system-with-pharmaceutical-applications 2025-08-20T13:53:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illuminated-extractors-secures-patent-for-revolutionary-cryogenic-refrigeration-system-with-pharmaceutical-applications 2025-08-20T13:53:32+00:00 hourly 0.9 https://trial.medpath.com/news/alzecure-pharma-strengthens-clinical-development-team-with-appointment-of-cecilia-wadell-as-head-of-development 2025-08-20T13:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzecure-pharma-strengthens-clinical-development-team-with-appointment-of-cecilia-wadell-as-head-of-development 2025-08-20T13:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/brazilian-researchers-develop-novel-zika-vaccine-using-virus-like-particles-preventing-brain-and-testicular-damage 2025-08-20T13:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazilian-researchers-develop-novel-zika-vaccine-using-virus-like-particles-preventing-brain-and-testicular-damage 2025-08-20T13:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/neurovalens-secures-ps6m-to-expand-fda-approved-neurostimulation-devices-for-mental-health 2025-08-20T13:05:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurovalens-secures-ps6m-to-expand-fda-approved-neurostimulation-devices-for-mental-health 2025-08-20T13:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/india-advances-rare-disease-treatment-pipeline-with-nine-new-medications 2025-08-20T13:05:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-advances-rare-disease-treatment-pipeline-with-nine-new-medications 2025-08-20T13:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/natco-pharma-launches-generic-bosentan-for-pediatric-pulmonary-arterial-hypertension-with-180-day-us-market-exclusivity 2025-08-20T13:04:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natco-pharma-launches-generic-bosentan-for-pediatric-pulmonary-arterial-hypertension-with-180-day-us-market-exclusivity 2025-08-20T13:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/envoy-medical-secures-three-new-patents-for-fully-implantable-cochlear-implant-technology 2025-08-20T12:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/envoy-medical-secures-three-new-patents-for-fully-implantable-cochlear-implant-technology 2025-08-20T12:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-continuous-glucose-monitor-for-weight-management-beyond-diabetes 2025-08-20T09:04:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-continuous-glucose-monitor-for-weight-management-beyond-diabetes 2025-08-20T09:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/circle-pharma-s-novel-cyclin-inhibitor-shows-promise-against-e2f-driven-cancers-in-nature-study 2025-08-20T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circle-pharma-s-novel-cyclin-inhibitor-shows-promise-against-e2f-driven-cancers-in-nature-study 2025-08-20T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-major-shift-in-type-2-diabetes-treatment-with-earlier-access-to-sglt-2-inhibitors-and-weight-loss-drugs 2025-08-20T05:37:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-recommends-major-shift-in-type-2-diabetes-treatment-with-earlier-access-to-sglt-2-inhibitors-and-weight-loss-drugs 2025-08-20T05:37:19+00:00 hourly 0.9 https://trial.medpath.com/news/invion-s-inv043-receives-fda-orphan-drug-designation-for-anal-cancer-treatment 2025-08-20T05:36:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invion-s-inv043-receives-fda-orphan-drug-designation-for-anal-cancer-treatment 2025-08-20T05:36:05+00:00 hourly 0.9 https://trial.medpath.com/news/ruxolitinib-maintains-long-term-efficacy-in-polycythemia-vera-and-myelofibrosis-despite-emergence-of-novel-jak-inhibitors 2025-08-20T03:38:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ruxolitinib-maintains-long-term-efficacy-in-polycythemia-vera-and-myelofibrosis-despite-emergence-of-novel-jak-inhibitors 2025-08-20T03:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/wistar-institute-launches-17-million-personalized-hiv-cure-initiative-with-six-component-therapy-approach 2025-08-20T01:45:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wistar-institute-launches-17-million-personalized-hiv-cure-initiative-with-six-component-therapy-approach 2025-08-20T01:45:36+00:00 hourly 0.9 https://trial.medpath.com/news/celldex-s-barzolvolimab-phase-2-trial-provides-key-insights-into-mast-cell-role-in-eosinophilic-esophagitis 2025-08-20T01:43:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celldex-s-barzolvolimab-phase-2-trial-provides-key-insights-into-mast-cell-role-in-eosinophilic-esophagitis 2025-08-20T01:43:39+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-upholds-patent-cancellation-for-dexcom-glucose-monitor-sensor-technology 2025-08-20T01:43:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-upholds-patent-cancellation-for-dexcom-glucose-monitor-sensor-technology 2025-08-20T01:43:34+00:00 hourly 0.9 https://trial.medpath.com/news/arc-therapies-advances-yb328-gut-microbe-research-toward-cancer-immunotherapy-clinical-trials 2025-08-20T01:42:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arc-therapies-advances-yb328-gut-microbe-research-toward-cancer-immunotherapy-clinical-trials 2025-08-20T01:42:39+00:00 hourly 0.9 https://trial.medpath.com/news/radioparp-phase-1-trial-demonstrates-safety-of-olaparib-combined-with-radiotherapy-in-triple-negative-breast-cancer 2025-08-20T01:42:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radioparp-phase-1-trial-demonstrates-safety-of-olaparib-combined-with-radiotherapy-in-triple-negative-breast-cancer 2025-08-20T01:42:36+00:00 hourly 0.9 https://trial.medpath.com/news/friends-of-cancer-research-partners-with-mms-to-develop-framework-for-interpreting-interim-overall-survival-data-in-oncology-trials 2025-08-20T01:39:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/friends-of-cancer-research-partners-with-mms-to-develop-framework-for-interpreting-interim-overall-survival-data-in-oncology-trials 2025-08-20T01:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/merit-medical-enrolls-first-patient-in-wrapsody-registry-for-hemodialysis-vascular-access 2025-08-20T01:39:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merit-medical-enrolls-first-patient-in-wrapsody-registry-for-hemodialysis-vascular-access 2025-08-20T01:39:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-uncertainties-about-cancer-drugs-largely-missing-from-medical-literature-and-guidelines 2025-08-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-uncertainties-about-cancer-drugs-largely-missing-from-medical-literature-and-guidelines 2025-08-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/viking-therapeutics-phase-2-oral-obesity-trial-results-generate-mixed-market-response 2025-08-19T21:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viking-therapeutics-phase-2-oral-obesity-trial-results-generate-mixed-market-response 2025-08-19T21:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-iovance-s-amtagvi-as-first-t-cell-therapy-for-solid-tumors-in-canada 2025-08-19T21:48:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-iovance-s-amtagvi-as-first-t-cell-therapy-for-solid-tumors-in-canada 2025-08-19T21:48:26+00:00 hourly 0.9 https://trial.medpath.com/news/belhaven-biopharma-secures-oversubscribed-series-a-funding-to-advance-first-dry-powder-nasal-epinephrine-therapy 2025-08-19T21:44:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belhaven-biopharma-secures-oversubscribed-series-a-funding-to-advance-first-dry-powder-nasal-epinephrine-therapy 2025-08-19T21:44:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-nipocalimab-for-myasthenia-gravis-as-pipeline-advances-with-20-novel-therapies 2025-08-19T21:43:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-nipocalimab-for-myasthenia-gravis-as-pipeline-advances-with-20-novel-therapies 2025-08-19T21:43:52+00:00 hourly 0.9 https://trial.medpath.com/news/pcv21-pneumococcal-vaccine-demonstrates-favorable-immunogenicity-in-pediatric-phase-2-trial 2025-08-19T21:43:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pcv21-pneumococcal-vaccine-demonstrates-favorable-immunogenicity-in-pediatric-phase-2-trial 2025-08-19T21:43:43+00:00 hourly 0.9 https://trial.medpath.com/news/greenwich-lifesciences-builds-internal-clinical-team-to-reduce-costs-and-enhance-flamingo-01-breast-cancer-trial-operations 2025-08-19T21:42:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenwich-lifesciences-builds-internal-clinical-team-to-reduce-costs-and-enhance-flamingo-01-breast-cancer-trial-operations 2025-08-19T21:42:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-new-draft-guidance-for-optimizing-radiopharmaceutical-dosing-in-cancer-clinical-trials 2025-08-19T21:42:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-new-draft-guidance-for-optimizing-radiopharmaceutical-dosing-in-cancer-clinical-trials 2025-08-19T21:42:11+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-launch-world-s-first-long-covid-diagnostic-test-trial 2025-08-19T21:41:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-researchers-launch-world-s-first-long-covid-diagnostic-test-trial 2025-08-19T21:41:44+00:00 hourly 0.9 https://trial.medpath.com/news/biosimilar-laronidase-shows-comparable-efficacy-to-reference-drug-in-mps-i-patients 2025-08-19T21:40:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biosimilar-laronidase-shows-comparable-efficacy-to-reference-drug-in-mps-i-patients 2025-08-19T21:40:15+00:00 hourly 0.9 https://trial.medpath.com/news/nutraland-usa-and-youthorin-biotechnology-partner-to-develop-next-generation-probiotic-and-anti-aging-ingredients 2025-08-19T21:38:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nutraland-usa-and-youthorin-biotechnology-partner-to-develop-next-generation-probiotic-and-anti-aging-ingredients 2025-08-19T21:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/beginngs-newborn-genome-screening-program-expands-to-qatar-in-first-international-collaboration 2025-08-19T21:37:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beginngs-newborn-genome-screening-program-expands-to-qatar-in-first-international-collaboration 2025-08-19T21:37:57+00:00 hourly 0.9 https://trial.medpath.com/news/eight-sleep-secures-100m-series-d-to-advance-ai-powered-sleep-technology-and-medical-applications 2025-08-19T21:37:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eight-sleep-secures-100m-series-d-to-advance-ai-powered-sleep-technology-and-medical-applications 2025-08-19T21:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-darzalex-faspro-in-newly-diagnosed-multiple-myeloma 2025-08-19T21:37:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-darzalex-faspro-in-newly-diagnosed-multiple-myeloma 2025-08-19T21:37:29+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-oklahoma-researchers-unlock-amylin-receptor-mechanisms-for-next-generation-obesity-drugs 2025-08-19T21:37:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-oklahoma-researchers-unlock-amylin-receptor-mechanisms-for-next-generation-obesity-drugs 2025-08-19T21:37:21+00:00 hourly 0.9 https://trial.medpath.com/news/fsgs-treatment-landscape-approaches-critical-inflection-point-as-multiple-novel-therapies-near-approval 2025-08-19T21:37:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fsgs-treatment-landscape-approaches-critical-inflection-point-as-multiple-novel-therapies-near-approval 2025-08-19T21:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/psoriasis-care-evolves-beyond-skin-deep-new-therapies-and-patient-centered-approaches-transform-treatment-landscape 2025-08-19T20:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psoriasis-care-evolves-beyond-skin-deep-new-therapies-and-patient-centered-approaches-transform-treatment-landscape 2025-08-19T20:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/cour-pharma-initiates-first-in-class-type-1-diabetes-trial-with-cnp-103-nanoparticle-therapy 2025-08-19T17:55:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cour-pharma-initiates-first-in-class-type-1-diabetes-trial-with-cnp-103-nanoparticle-therapy 2025-08-19T17:55:44+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-ozempic-for-kidney-protection-in-type-2-diabetes-patients 2025-08-19T17:47:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-ozempic-for-kidney-protection-in-type-2-diabetes-patients 2025-08-19T17:47:22+00:00 hourly 0.9 https://trial.medpath.com/news/xspray-pharma-submits-improved-nilotinib-formulation-xs003-to-fda-for-chronic-myeloid-leukemia-treatment 2025-08-19T17:47:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xspray-pharma-submits-improved-nilotinib-formulation-xs003-to-fda-for-chronic-myeloid-leukemia-treatment 2025-08-19T17:47:06+00:00 hourly 0.9 https://trial.medpath.com/news/kelonia-therapeutics-doses-first-patient-in-groundbreaking-in-vivo-car-t-trial-for-multiple-myeloma 2025-08-19T17:45:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelonia-therapeutics-doses-first-patient-in-groundbreaking-in-vivo-car-t-trial-for-multiple-myeloma 2025-08-19T17:45:31+00:00 hourly 0.9 https://trial.medpath.com/news/evofem-biosciences-secures-patent-protection-for-solosec-through-2041-strengthening-market-position-for-single-dose-sti-treatment 2025-08-19T17:45:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evofem-biosciences-secures-patent-protection-for-solosec-through-2041-strengthening-market-position-for-single-dose-sti-treatment 2025-08-19T17:45:23+00:00 hourly 0.9 https://trial.medpath.com/news/delcath-systems-initiates-phase-2-trial-of-hepzato-for-liver-dominant-metastatic-colorectal-cancer 2025-08-19T17:44:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delcath-systems-initiates-phase-2-trial-of-hepzato-for-liver-dominant-metastatic-colorectal-cancer 2025-08-19T17:44:45+00:00 hourly 0.9 https://trial.medpath.com/news/ashibio-licenses-vantictumab-for-rare-bone-disease-ado2-in-strategic-pipeline-expansion 2025-08-19T17:44:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ashibio-licenses-vantictumab-for-rare-bone-disease-ado2-in-strategic-pipeline-expansion 2025-08-19T17:44:38+00:00 hourly 0.9 https://trial.medpath.com/news/corrixr-therapeutics-secures-1m-delaware-investment-to-advance-crispr-based-cancer-gene-therapy 2025-08-19T17:44:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corrixr-therapeutics-secures-1m-delaware-investment-to-advance-crispr-based-cancer-gene-therapy 2025-08-19T17:44:07+00:00 hourly 0.9 https://trial.medpath.com/news/axelyf-closes-2-6m-seed-round-to-advance-superior-rna-lnp-gene-editing-technology 2025-08-19T17:43:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axelyf-closes-2-6m-seed-round-to-advance-superior-rna-lnp-gene-editing-technology 2025-08-19T17:43:40+00:00 hourly 0.9 https://trial.medpath.com/news/tenofovir-amibufenamide-shows-significant-efficacy-in-chronic-hepatitis-b-patients-with-normal-alt-levels 2025-08-19T17:43:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenofovir-amibufenamide-shows-significant-efficacy-in-chronic-hepatitis-b-patients-with-normal-alt-levels 2025-08-19T17:43:02+00:00 hourly 0.9 https://trial.medpath.com/news/conflicting-evidence-emerges-on-ketamine-s-effectiveness-for-chronic-pain-management 2025-08-19T17:42:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conflicting-evidence-emerges-on-ketamine-s-effectiveness-for-chronic-pain-management 2025-08-19T17:42:24+00:00 hourly 0.9 https://trial.medpath.com/news/novel-kappa-opioid-receptor-agonist-anrikefon-shows-superior-efficacy-in-treating-chronic-kidney-disease-associated-pruritus 2025-08-19T17:42:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-kappa-opioid-receptor-agonist-anrikefon-shows-superior-efficacy-in-treating-chronic-kidney-disease-associated-pruritus 2025-08-19T17:42:15+00:00 hourly 0.9 https://trial.medpath.com/news/neuroone-secures-fda-clearance-for-onerf-trigeminal-nerve-ablation-system-to-treat-chronic-facial-pain 2025-08-19T17:41:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuroone-secures-fda-clearance-for-onerf-trigeminal-nerve-ablation-system-to-treat-chronic-facial-pain 2025-08-19T17:41:42+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-stock-surges-6-following-fda-approval-boost-amid-pipeline-developments 2025-08-19T17:41:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-stock-surges-6-following-fda-approval-boost-amid-pipeline-developments 2025-08-19T17:41:40+00:00 hourly 0.9 https://trial.medpath.com/news/transcelerate-and-fda-release-framework-to-scale-pragmatic-clinical-trials-in-routine-care-settings 2025-08-19T17:41:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcelerate-and-fda-release-framework-to-scale-pragmatic-clinical-trials-in-routine-care-settings 2025-08-19T17:41:03+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-launches-phase-2-trial-of-anktiva-for-long-covid-treatment 2025-08-19T17:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitybio-launches-phase-2-trial-of-anktiva-for-long-covid-treatment 2025-08-19T17:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/scripps-research-launches-fully-remote-clinical-trial-for-long-covid-treatment-using-repurposed-drug 2025-08-19T17:40:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scripps-research-launches-fully-remote-clinical-trial-for-long-covid-treatment-using-repurposed-drug 2025-08-19T17:40:44+00:00 hourly 0.9 https://trial.medpath.com/news/vasthera-receives-fda-clearance-for-phase-1-trial-of-novel-pah-drug-vtb-10 2025-08-19T13:39:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vasthera-receives-fda-clearance-for-phase-1-trial-of-novel-pah-drug-vtb-10 2025-08-19T13:39:07+00:00 hourly 0.9 https://trial.medpath.com/news/knightsbridge-and-camelot-biocapital-partner-to-transform-biotech-funding-through-blockchain-technology 2025-08-19T13:38:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/knightsbridge-and-camelot-biocapital-partner-to-transform-biotech-funding-through-blockchain-technology 2025-08-19T13:38:56+00:00 hourly 0.9 https://trial.medpath.com/news/pcsk9-inhibitors-demonstrate-efficacy-and-safety-in-chronic-kidney-disease-patients-including-advanced-stages 2025-08-19T13:38:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pcsk9-inhibitors-demonstrate-efficacy-and-safety-in-chronic-kidney-disease-patients-including-advanced-stages 2025-08-19T13:38:52+00:00 hourly 0.9 https://trial.medpath.com/news/aprogen-s-pmc-309-shows-early-anticancer-activity-in-phase-1-trial-advances-to-higher-dose-testing 2025-08-19T13:38:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aprogen-s-pmc-309-shows-early-anticancer-activity-in-phase-1-trial-advances-to-higher-dose-testing 2025-08-19T13:38:47+00:00 hourly 0.9 https://trial.medpath.com/news/china-medical-system-s-mg-k10-advances-to-phase-iii-trials-for-chronic-spontaneous-urticaria-treatment 2025-08-19T13:38:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-medical-system-s-mg-k10-advances-to-phase-iii-trials-for-chronic-spontaneous-urticaria-treatment 2025-08-19T13:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/teleflex-launches-barrigel-rectal-spacer-in-japan-following-pmda-approval-for-prostate-cancer-radiation-protection 2025-08-19T13:37:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teleflex-launches-barrigel-rectal-spacer-in-japan-following-pmda-approval-for-prostate-cancer-radiation-protection 2025-08-19T13:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/luzhu-biotechnology-s-lz901-herpes-zoster-vaccine-advances-through-clinical-development-with-strong-safety-profile 2025-08-19T09:45:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luzhu-biotechnology-s-lz901-herpes-zoster-vaccine-advances-through-clinical-development-with-strong-safety-profile 2025-08-19T09:45:04+00:00 hourly 0.9 https://trial.medpath.com/news/csl-to-spin-off-seqirus-vaccine-unit-and-launch-487m-share-buyback-in-major-restructuring 2025-08-19T09:43:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csl-to-spin-off-seqirus-vaccine-unit-and-launch-487m-share-buyback-in-major-restructuring 2025-08-19T09:43:11+00:00 hourly 0.9 https://trial.medpath.com/news/jcyte-initiates-phase-2-trial-of-famzeretcel-cell-therapy-for-retinitis-pigmentosa 2025-08-19T09:35:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jcyte-initiates-phase-2-trial-of-famzeretcel-cell-therapy-for-retinitis-pigmentosa 2025-08-19T09:35:39+00:00 hourly 0.9 https://trial.medpath.com/news/biomed-x-and-novo-nordisk-partner-to-advance-oral-peptide-drug-delivery-technology 2025-08-19T09:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomed-x-and-novo-nordisk-partner-to-advance-oral-peptide-drug-delivery-technology 2025-08-19T09:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/tenon-medical-launches-catamaran-se-si-joint-fusion-system-with-reduced-profile-design 2025-08-19T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenon-medical-launches-catamaran-se-si-joint-fusion-system-with-reduced-profile-design 2025-08-19T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/oric-pharmaceuticals-appoints-kevin-brodbeck-as-chief-technical-officer-ahead-of-phase-3-trials 2025-08-19T05:37:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oric-pharmaceuticals-appoints-kevin-brodbeck-as-chief-technical-officer-ahead-of-phase-3-trials 2025-08-19T05:37:57+00:00 hourly 0.9 https://trial.medpath.com/news/remegen-and-santen-strike-1-3-billion-licensing-deal-for-dual-target-ophthalmic-drug-rc28-e 2025-08-19T05:37:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remegen-and-santen-strike-1-3-billion-licensing-deal-for-dual-target-ophthalmic-drug-rc28-e 2025-08-19T05:37:07+00:00 hourly 0.9 https://trial.medpath.com/news/multimodal-ai-model-predicts-egfr-tki-treatment-outcomes-in-advanced-nsclc-patients 2025-08-19T05:37:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multimodal-ai-model-predicts-egfr-tki-treatment-outcomes-in-advanced-nsclc-patients 2025-08-19T05:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-testing-and-targeted-therapies-transform-treatment-landscape-for-pediatric-low-grade-gliomas 2025-08-19T03:05:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-testing-and-targeted-therapies-transform-treatment-landscape-for-pediatric-low-grade-gliomas 2025-08-19T03:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/ozempic-faces-2-billion-in-lawsuits-over-severe-side-effects-including-stomach-paralysis-and-vision-loss 2025-08-19T01:44:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ozempic-faces-2-billion-in-lawsuits-over-severe-side-effects-including-stomach-paralysis-and-vision-loss 2025-08-19T01:44:04+00:00 hourly 0.9 https://trial.medpath.com/news/iranian-company-launches-spartina-domestic-tirzepatide-for-type-2-diabetes-and-obesity-treatment 2025-08-19T01:39:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iranian-company-launches-spartina-domestic-tirzepatide-for-type-2-diabetes-and-obesity-treatment 2025-08-19T01:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-s-pemgarda-maintains-neutralizing-activity-against-dominant-xfg-covid-19-variant 2025-08-19T01:39:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivyd-s-pemgarda-maintains-neutralizing-activity-against-dominant-xfg-covid-19-variant 2025-08-19T01:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/self-powered-microneedle-patch-enables-painless-biomarker-monitoring-without-blood-draws 2025-08-19T01:38:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/self-powered-microneedle-patch-enables-painless-biomarker-monitoring-without-blood-draws 2025-08-19T01:38:39+00:00 hourly 0.9 https://trial.medpath.com/news/roche-canada-secures-public-funding-for-vabysmo-in-quebec-for-retinal-vein-occlusion-treatment 2025-08-19T01:38:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-canada-secures-public-funding-for-vabysmo-in-quebec-for-retinal-vein-occlusion-treatment 2025-08-19T01:38:09+00:00 hourly 0.9 https://trial.medpath.com/news/over-the-counter-birth-control-pill-dramatically-increases-contraceptive-access-among-underserved-populations 2025-08-19T01:37:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/over-the-counter-birth-control-pill-dramatically-increases-contraceptive-access-among-underserved-populations 2025-08-19T01:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-prioritizing-overall-survival-as-primary-endpoint-for-cancer-drug-approvals 2025-08-19T01:36:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-draft-guidance-prioritizing-overall-survival-as-primary-endpoint-for-cancer-drug-approvals 2025-08-19T01:36:40+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-vabysmo-shows-sustained-efficacy-over-four-years-in-neovascular-amd-and-delivers-vision-gains-in-difficult-to-treat-asian-subtype 2025-08-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-vabysmo-shows-sustained-efficacy-over-four-years-in-neovascular-amd-and-delivers-vision-gains-in-difficult-to-treat-asian-subtype 2025-08-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vcu-massey-becomes-first-virginia-center-to-offer-fda-approved-til-therapy-for-advanced-melanoma 2025-08-18T21:44:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vcu-massey-becomes-first-virginia-center-to-offer-fda-approved-til-therapy-for-advanced-melanoma 2025-08-18T21:44:23+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-receives-ema-approval-for-ireland-manufacturing-facility-advancing-global-dual-sourcing-strategy 2025-08-18T21:44:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-biologics-receives-ema-approval-for-ireland-manufacturing-facility-advancing-global-dual-sourcing-strategy 2025-08-18T21:44:15+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-class-monoclonal-antibody-shows-promise-against-sepsis-induced-immune-dysregulation 2025-08-18T21:43:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-class-monoclonal-antibody-shows-promise-against-sepsis-induced-immune-dysregulation 2025-08-18T21:43:34+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-houston-develops-first-spleen-targeted-nanoparticle-system-for-lupus-treatment 2025-08-18T21:43:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-houston-develops-first-spleen-targeted-nanoparticle-system-for-lupus-treatment 2025-08-18T21:43:32+00:00 hourly 0.9 https://trial.medpath.com/news/novel-monoclonal-antibody-stapokibart-demonstrates-significant-efficacy-in-severe-chronic-rhinosinusitis-with-nasal-polyps 2025-08-18T21:43:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-monoclonal-antibody-stapokibart-demonstrates-significant-efficacy-in-severe-chronic-rhinosinusitis-with-nasal-polyps 2025-08-18T21:43:30+00:00 hourly 0.9 https://trial.medpath.com/news/dnl343-shows-promise-as-first-in-class-eif2b-activator-for-als-treatment-in-phase-1-clinical-trial 2025-08-18T21:41:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dnl343-shows-promise-as-first-in-class-eif2b-activator-for-als-treatment-in-phase-1-clinical-trial 2025-08-18T21:41:19+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-initiates-first-patent-litigation-against-pertuzumab-biosimilar-hlx11 2025-08-18T21:40:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-initiates-first-patent-litigation-against-pertuzumab-biosimilar-hlx11 2025-08-18T21:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/propanc-biopharma-surges-150-following-nasdaq-uplisting-and-fda-orphan-drug-designations 2025-08-18T21:40:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/propanc-biopharma-surges-150-following-nasdaq-uplisting-and-fda-orphan-drug-designations 2025-08-18T21:40:10+00:00 hourly 0.9 https://trial.medpath.com/news/qihan-biotech-receives-fda-clearance-for-qt-019b-first-universal-dual-target-car-t-therapy-for-refractory-lupus 2025-08-18T21:40:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qihan-biotech-receives-fda-clearance-for-qt-019b-first-universal-dual-target-car-t-therapy-for-refractory-lupus 2025-08-18T21:40:08+00:00 hourly 0.9 https://trial.medpath.com/news/livanova-launches-essenz-perfusion-system-in-china-following-nmpa-approval 2025-08-18T21:40:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/livanova-launches-essenz-perfusion-system-in-china-following-nmpa-approval 2025-08-18T21:40:06+00:00 hourly 0.9 https://trial.medpath.com/news/natera-s-signatera-assay-shows-promise-in-phase-iii-bladder-cancer-trial-seeks-fda-approval 2025-08-18T21:39:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-s-signatera-assay-shows-promise-in-phase-iii-bladder-cancer-trial-seeks-fda-approval 2025-08-18T21:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/cantargia-appoints-biotech-veteran-dr-hilde-steineger-as-ceo-to-lead-il1rap-targeted-therapy-development 2025-08-18T21:39:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cantargia-appoints-biotech-veteran-dr-hilde-steineger-as-ceo-to-lead-il1rap-targeted-therapy-development 2025-08-18T21:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/atropos-health-and-novartis-partner-to-deploy-ai-for-faster-rare-disease-diagnosis-in-pnh-patients 2025-08-18T21:38:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atropos-health-and-novartis-partner-to-deploy-ai-for-faster-rare-disease-diagnosis-in-pnh-patients 2025-08-18T21:38:25+00:00 hourly 0.9 https://trial.medpath.com/news/novel-buprenorphine-protocol-eliminates-withdrawal-requirement-for-opioid-use-disorder-treatment 2025-08-18T17:51:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-buprenorphine-protocol-eliminates-withdrawal-requirement-for-opioid-use-disorder-treatment 2025-08-18T17:51:17+00:00 hourly 0.9 https://trial.medpath.com/news/impact-biomedical-secures-patent-for-plant-based-antimicrobial-technology-targeting-infectious-diseases 2025-08-18T17:48:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/impact-biomedical-secures-patent-for-plant-based-antimicrobial-technology-targeting-infectious-diseases 2025-08-18T17:48:40+00:00 hourly 0.9 https://trial.medpath.com/news/oman-achieves-medical-milestone-with-first-successful-car-t-cell-therapy-implementation 2025-08-18T17:46:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oman-achieves-medical-milestone-with-first-successful-car-t-cell-therapy-implementation 2025-08-18T17:46:36+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-industry-accelerates-glp-1-injectable-manufacturing-and-delivery-innovation-to-meet-surging-global-demand 2025-08-18T17:46:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-industry-accelerates-glp-1-injectable-manufacturing-and-delivery-innovation-to-meet-surging-global-demand 2025-08-18T17:46:21+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharm-reports-strong-h1-2025-results-with-27-growth-in-innovative-drug-sales-and-strategic-lanova-acquisition 2025-08-18T17:46:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sino-biopharm-reports-strong-h1-2025-results-with-27-growth-in-innovative-drug-sales-and-strategic-lanova-acquisition 2025-08-18T17:46:16+00:00 hourly 0.9 https://trial.medpath.com/news/upperton-pharma-and-oxford-university-secure-funding-to-develop-needle-free-oral-adenovirus-vaccine-platform 2025-08-18T17:45:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upperton-pharma-and-oxford-university-secure-funding-to-develop-needle-free-oral-adenovirus-vaccine-platform 2025-08-18T17:45:57+00:00 hourly 0.9 https://trial.medpath.com/news/ravicti-receives-regulatory-approval-in-saudi-arabia-qatar-and-kuwait-for-urea-cycle-disorders 2025-08-18T17:45:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ravicti-receives-regulatory-approval-in-saudi-arabia-qatar-and-kuwait-for-urea-cycle-disorders 2025-08-18T17:45:32+00:00 hourly 0.9 https://trial.medpath.com/news/viewsml-and-iprocess-form-strategic-partnership-to-accelerate-ai-powered-virtual-biomarker-testing 2025-08-18T17:45:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viewsml-and-iprocess-form-strategic-partnership-to-accelerate-ai-powered-virtual-biomarker-testing 2025-08-18T17:45:06+00:00 hourly 0.9 https://trial.medpath.com/news/capricor-therapeutics-initiates-first-in-human-trial-of-stealthx-exosome-based-vaccine-platform 2025-08-18T17:43:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capricor-therapeutics-initiates-first-in-human-trial-of-stealthx-exosome-based-vaccine-platform 2025-08-18T17:43:45+00:00 hourly 0.9 https://trial.medpath.com/news/genprex-secures-key-patents-for-reqorsa-gene-therapy-combinations-with-checkpoint-inhibitors 2025-08-18T17:43:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genprex-secures-key-patents-for-reqorsa-gene-therapy-combinations-with-checkpoint-inhibitors 2025-08-18T17:43:35+00:00 hourly 0.9 https://trial.medpath.com/news/opus-genetics-receives-fda-clearance-for-best1-gene-therapy-trial-in-rare-inherited-retinal-disease 2025-08-18T17:43:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opus-genetics-receives-fda-clearance-for-best1-gene-therapy-trial-in-rare-inherited-retinal-disease 2025-08-18T17:43:09+00:00 hourly 0.9 https://trial.medpath.com/news/accord-biopharma-launches-imuldosa-biosimilar-at-92-discount-to-stelara 2025-08-18T17:43:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accord-biopharma-launches-imuldosa-biosimilar-at-92-discount-to-stelara 2025-08-18T17:43:07+00:00 hourly 0.9 https://trial.medpath.com/news/influenza-pipeline-surges-with-120-therapies-as-moderna-astrazeneca-lead-innovation-wave 2025-08-18T17:42:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/influenza-pipeline-surges-with-120-therapies-as-moderna-astrazeneca-lead-innovation-wave 2025-08-18T17:42:27+00:00 hourly 0.9 https://trial.medpath.com/news/quoin-pharmaceuticals-appoints-sally-lawlor-as-cfo-to-navigate-qrx003-commercialization 2025-08-18T17:41:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quoin-pharmaceuticals-appoints-sally-lawlor-as-cfo-to-navigate-qrx003-commercialization 2025-08-18T17:41:36+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-partners-with-skyhawk-therapeutics-in-2-billion-rna-splicing-collaboration-for-neurological-disorders 2025-08-18T17:41:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-partners-with-skyhawk-therapeutics-in-2-billion-rna-splicing-collaboration-for-neurological-disorders 2025-08-18T17:41:05+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-biopharma-receives-1-1-million-in-talicia-licensing-payments-following-first-international-launch 2025-08-18T17:41:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-biopharma-receives-1-1-million-in-talicia-licensing-payments-following-first-international-launch 2025-08-18T17:41:01+00:00 hourly 0.9 https://trial.medpath.com/news/newamsterdam-s-obicetrapib-receives-ema-validation-for-european-review-following-positive-phase-3-results 2025-08-18T17:38:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newamsterdam-s-obicetrapib-receives-ema-validation-for-european-review-following-positive-phase-3-results 2025-08-18T17:38:59+00:00 hourly 0.9 https://trial.medpath.com/news/nanoviricides-nv-387-antiviral-drug-shows-potential-to-prevent-cancer-metastasis-resurgence-through-anti-inflammatory-effects 2025-08-18T17:37:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoviricides-nv-387-antiviral-drug-shows-potential-to-prevent-cancer-metastasis-resurgence-through-anti-inflammatory-effects 2025-08-18T17:37:42+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-and-veeva-systems-form-strategic-partnership-to-accelerate-clinical-development-and-commercial-operations 2025-08-18T17:37:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqvia-and-veeva-systems-form-strategic-partnership-to-accelerate-clinical-development-and-commercial-operations 2025-08-18T17:37:27+00:00 hourly 0.9 https://trial.medpath.com/news/multi-omics-reveals-tumor-draining-lymph-nodes-as-critical-hubs-for-cancer-immunotherapy 2025-08-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-omics-reveals-tumor-draining-lymph-nodes-as-critical-hubs-for-cancer-immunotherapy 2025-08-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapies-advance-against-infectious-diseases-as-ebt-101-becomes-first-hiv-gene-editing-treatment-in-human-trials 2025-08-18T13:41:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-therapies-advance-against-infectious-diseases-as-ebt-101-becomes-first-hiv-gene-editing-treatment-in-human-trials 2025-08-18T13:41:36+00:00 hourly 0.9 https://trial.medpath.com/news/unicycive-therapeutics-secures-patent-protection-for-uni-494-kidney-disease-treatment-through-2040 2025-08-18T13:41:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unicycive-therapeutics-secures-patent-protection-for-uni-494-kidney-disease-treatment-through-2040 2025-08-18T13:41:11+00:00 hourly 0.9 https://trial.medpath.com/news/luna-health-secures-23-6m-series-a-to-advance-nighttime-insulin-patch-pump-for-pen-users 2025-08-18T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luna-health-secures-23-6m-series-a-to-advance-nighttime-insulin-patch-pump-for-pen-users 2025-08-18T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/jnk-pathway-suppression-identified-as-key-driver-of-treatment-resistance-in-er-breast-cancer 2025-08-18T13:40:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jnk-pathway-suppression-identified-as-key-driver-of-treatment-resistance-in-er-breast-cancer 2025-08-18T13:40:02+00:00 hourly 0.9 https://trial.medpath.com/news/aster-70-trial-shows-no-survival-benefit-from-adjuvant-chemotherapy-in-elderly-breast-cancer-patients 2025-08-18T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aster-70-trial-shows-no-survival-benefit-from-adjuvant-chemotherapy-in-elderly-breast-cancer-patients 2025-08-18T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-imvigor011-trial-demonstrates-significant-survival-benefits-for-ctdna-guided-bladder-cancer-treatment 2025-08-18T13:39:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-imvigor011-trial-demonstrates-significant-survival-benefits-for-ctdna-guided-bladder-cancer-treatment 2025-08-18T13:39:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reinstates-sarepta-s-elevidys-gene-therapy-following-parent-advocacy-despite-failed-trial 2025-08-18T13:39:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reinstates-sarepta-s-elevidys-gene-therapy-following-parent-advocacy-despite-failed-trial 2025-08-18T13:39:34+00:00 hourly 0.9 https://trial.medpath.com/news/outlook-therapeutics-awaits-critical-fda-decision-for-wet-amd-treatment-ons-5010 2025-08-18T13:38:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outlook-therapeutics-awaits-critical-fda-decision-for-wet-amd-treatment-ons-5010 2025-08-18T13:38:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-bristol-myers-squibb-and-systimmune-s-iza-bren-for-advanced-egfr-mutant-lung-cancer 2025-08-18T13:37:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-bristol-myers-squibb-and-systimmune-s-iza-bren-for-advanced-egfr-mutant-lung-cancer 2025-08-18T13:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-commissioner-launches-controversial-expert-panels-with-financial-conflicts-raising-transparency-concerns 2025-08-18T13:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-commissioner-launches-controversial-expert-panels-with-financial-conflicts-raising-transparency-concerns 2025-08-18T13:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/smartalpha-s-nerveblox-ai-software-receives-fda-510-k-clearance-for-ultrasound-guided-regional-anesthesia 2025-08-18T11:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smartalpha-s-nerveblox-ai-software-receives-fda-510-k-clearance-for-ultrasound-guided-regional-anesthesia 2025-08-18T11:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/anocca-secures-46m-to-advance-europe-s-first-non-viral-gene-edited-tcr-t-therapy-for-pancreatic-cancer 2025-08-18T09:29:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anocca-secures-46m-to-advance-europe-s-first-non-viral-gene-edited-tcr-t-therapy-for-pancreatic-cancer 2025-08-18T09:29:42+00:00 hourly 0.9 https://trial.medpath.com/news/gc-biopharma-expands-asian-presence-with-thai-red-cross-partnership-for-plasma-derived-therapeutics 2025-08-18T05:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gc-biopharma-expands-asian-presence-with-thai-red-cross-partnership-for-plasma-derived-therapeutics 2025-08-18T05:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-releases-white-paper-on-selective-safety-data-collection-framework-for-late-stage-clinical-trials 2025-08-18T05:34:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-releases-white-paper-on-selective-safety-data-collection-framework-for-late-stage-clinical-trials 2025-08-18T05:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-receives-fda-approval-for-generic-tretinoin-cream-to-treat-acne-vulgaris 2025-08-18T04:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-receives-fda-approval-for-generic-tretinoin-cream-to-treat-acne-vulgaris 2025-08-18T04:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/musc-researchers-engineer-char-tregs-to-target-organ-rejection-with-precision-immunosuppression 2025-08-17T21:02:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/musc-researchers-engineer-char-tregs-to-target-organ-rejection-with-precision-immunosuppression 2025-08-17T21:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-gains-fda-approval-for-wegovy-in-liver-disease-treatment 2025-08-17T21:02:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-gains-fda-approval-for-wegovy-in-liver-disease-treatment 2025-08-17T21:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/enable-injections-secures-regulatory-approvals-for-enfuse-drug-delivery-system-in-brazil-and-uk 2025-08-17T21:02:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enable-injections-secures-regulatory-approvals-for-enfuse-drug-delivery-system-in-brazil-and-uk 2025-08-17T21:02:05+00:00 hourly 0.9 https://trial.medpath.com/news/sihuan-pharmaceutical-s-semaglutide-injection-advances-through-chinese-regulatory-pipeline-with-marketing-application-acceptance 2025-08-17T17:34:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sihuan-pharmaceutical-s-semaglutide-injection-advances-through-chinese-regulatory-pipeline-with-marketing-application-acceptance 2025-08-17T17:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/columbia-university-develops-mrna-based-universal-antiviral-therapy-inspired-by-rare-genetic-mutation 2025-08-17T17:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/columbia-university-develops-mrna-based-universal-antiviral-therapy-inspired-by-rare-genetic-mutation 2025-08-17T17:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/mscs-show-promise-for-rotator-cuff-repair-through-immune-modulation-and-tissue-engineering 2025-08-17T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mscs-show-promise-for-rotator-cuff-repair-through-immune-modulation-and-tissue-engineering 2025-08-17T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-s-china-manufacturing-facility-expected-to-reach-break-even-by-q3-fy26 2025-08-17T09:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurobindo-pharma-s-china-manufacturing-facility-expected-to-reach-break-even-by-q3-fy26 2025-08-17T09:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/palisade-bio-registers-8-9m-shares-for-resale-amid-financial-challenges-and-pali-2108-development 2025-08-17T05:30:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palisade-bio-registers-8-9m-shares-for-resale-amid-financial-challenges-and-pali-2108-development 2025-08-17T05:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trials-show-mango-consumption-improves-blood-sugar-control-in-type-2-diabetes-patients 2025-08-17T01:02:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trials-show-mango-consumption-improves-blood-sugar-control-in-type-2-diabetes-patients 2025-08-17T01:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/regulatory-t-cell-therapy-unexpectedly-promotes-pathogenic-th17-cell-generation-through-il-2-suppression 2025-08-16T21:36:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regulatory-t-cell-therapy-unexpectedly-promotes-pathogenic-th17-cell-generation-through-il-2-suppression 2025-08-16T21:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/kriya-therapeutics-raises-313m-to-advance-gene-therapy-pipeline-for-chronic-diseases 2025-08-16T21:35:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kriya-therapeutics-raises-313m-to-advance-gene-therapy-pipeline-for-chronic-diseases 2025-08-16T21:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/childhood-eoe-inflammation-control-reduces-esophageal-stiffening-and-complications-first-longitudinal-study-shows 2025-08-16T17:30:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/childhood-eoe-inflammation-control-reduces-esophageal-stiffening-and-complications-first-longitudinal-study-shows 2025-08-16T17:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/talphera-accelerates-nafamostat-trial-enrollment-with-strategic-site-optimization 2025-08-16T13:36:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/talphera-accelerates-nafamostat-trial-enrollment-with-strategic-site-optimization 2025-08-16T13:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-oxbryta-withdrawal-highlights-sickle-cell-disease-treatment-challenges-as-ema-extends-marketing-suspension 2025-08-16T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-oxbryta-withdrawal-highlights-sickle-cell-disease-treatment-challenges-as-ema-extends-marketing-suspension 2025-08-16T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/nationwide-study-reveals-critical-gaps-in-hpv-cancer-awareness-particularly-in-midwest-and-south 2025-08-16T13:32:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nationwide-study-reveals-critical-gaps-in-hpv-cancer-awareness-particularly-in-midwest-and-south 2025-08-16T13:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/hemorrhoids-treatment-pipeline-shows-promise-with-three-key-therapies-in-late-stage-development 2025-08-16T09:02:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemorrhoids-treatment-pipeline-shows-promise-with-three-key-therapies-in-late-stage-development 2025-08-16T09:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/fiocruz-and-ems-sign-historic-technology-transfer-agreement-for-glp-1-diabetes-and-obesity-drugs 2025-08-16T09:02:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fiocruz-and-ems-sign-historic-technology-transfer-agreement-for-glp-1-diabetes-and-obesity-drugs 2025-08-16T09:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/oregon-study-demonstrates-psilocybin-therapy-efficacy-for-low-income-adults-with-major-depression 2025-08-16T09:01:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oregon-study-demonstrates-psilocybin-therapy-efficacy-for-low-income-adults-with-major-depression 2025-08-16T09:01:22+00:00 hourly 0.9